

# Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019

GBD 2019 Tobacco Collaborators\*



## Summary

**Background** Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally.

**Methods** We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available.

**Findings** Globally in 2019, 1·14 billion (95% uncertainty interval 1·13–1·16) individuals were current smokers, who consumed 7·41 trillion (7·11–7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27·5% [26·5–28·5] reduction) and females (37·7% [35·4–39·9] reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0·99 billion (0·98–1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16–8·20) deaths and 200 million (185–214) disability-adjusted life-years, and was the leading risk factor for death among males (20·2% [19·3–21·1] of male deaths). 6·68 million [86·9%] of 7·69 million deaths attributable to smoking tobacco use were among current smokers.

**Interpretation** In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidence-based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens.

**Funding** Bloomberg Philanthropies and the Bill & Melinda Gates Foundation.

**Copyright** © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

## Introduction

Over the past 30 years, more than 200 million deaths have been caused by smoking tobacco use, and annual economic costs due to smoking tobacco use exceed US\$1 trillion.<sup>1,2</sup> With more than 1 billion current smokers globally in 2019, these numbers are likely to increase over the coming decades. The enormous health and economic consequences of the global tobacco epidemic make tobacco control a clear and urgent public health priority.<sup>3</sup> Effective implementation and enforcement of tobacco control policies and interventions can both increase healthy life expectancy and decrease health-care costs.<sup>4–7</sup> Despite the clear benefits, progress in tobacco control has varied substantially across countries.

The first international public health treaty, the WHO Framework Convention on Tobacco Control (FCTC),

entered into force and became an international binding law in 2005.<sup>8</sup> Consensus on the importance of tobacco control led 182 countries to ratify the treaty, which outlines a suite of recommended demand-reduction tools. These tools include reducing affordability through taxation, passing smoke-free laws, mandating health warnings on packaging, and banning tobacco advertising, promotion, and sponsorship.<sup>9</sup> 15 years after the FCTC entered into force, a large implementation gap remains. WHO has monitored the implementation of the FCTC articles using the MPOWER framework for more than a decade.<sup>10</sup> Over this period, only two countries, Brazil and Turkey, have implemented all the demand-reduction policies included in MPOWER at their highest level.<sup>10</sup> Nonetheless, progress has been made in expanding coverage of best-practice policies,

Lancet 2021; 397: 2337–60

Published Online  
May 27, 2021  
[https://doi.org/10.1016/S0140-6736\(21\)01169-7](https://doi.org/10.1016/S0140-6736(21)01169-7)

This online publication has been corrected. The corrected version first appeared at [thelancet.com](https://www.thelancet.com) on June 2, 2021

See [Comment](#) page 2310

\*Listed at the end of the Article

Correspondence to:  
Prof Emmanuela Gakidou,  
Institute for Health Metrics and  
Evaluation, University of  
Washington, Seattle,  
WA 98195 USA  
[gakidou@uw.edu](mailto:gakidou@uw.edu)

### Research in context

#### Evidence before this study

The importance of smoking tobacco use as a risk factor has resulted in a long history of estimating its prevalence and health effects using a variety of epidemiological methods. WHO produces biennial updates to estimates of prevalence of smoking tobacco use and the status of tobacco control policies around the world. The most recent global analysis of the burden of disease attributable to smoking was published on the basis of results from The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2015.

#### Added value of this study

This study, which is based on results from GBD 2019, updates and improves on previous estimates of the prevalence of smoking tobacco use and attributable disease burden. Compared with the GBD 2015 smoking prevalence and disease burden study, we have included more than 800 additional data sources on prevalence of smoking. In terms of methods, we developed and implemented a new unified approach to estimating the disease burden attributable to smoking tobacco use that addresses limitations of previous methods with direct estimation for all 36 causally linked health outcomes and reflecting dose-response associations among both current and former smokers. We estimated new continuous exposure

distributions, including distributions of age of initiation, cigarette-equivalents of tobacco smoked per day, pack-years, and years since cessation, and new cause-specific dose-response relative risk curves among both current and former smokers. These changes improve the reliability of estimates, particularly in low-income and middle-income countries, allow for disaggregation of disease burden by intensity of exposure, and also generate a multitude of new inputs that can be used by researchers and decision makers to inform and improve modelling studies.

#### Implications of all the available evidence

Smoking remains one of the most important risk factors for premature mortality and morbidity globally. Progress in reducing the prevalence of smoking tobacco use has varied widely, as has commitment to tobacco control across countries. Of concern, progress in many countries has slowed in the past 10 years and, with population growth, the total number of global smokers continues to increase. All countries must urgently adopt and enforce a comprehensive package of evidence-based policies to reduce the prevalence of current smoking and prevent initiation, particularly among adolescents and young adults.

with the number of countries implementing at least one best-practice policy increasing from 43 in 2007 to 136 in 2018.<sup>10</sup>

The global importance of non-communicable diseases has led to their inclusion at the forefront of global progress targets, including a goal of 25% reduction in premature mortality from non-communicable diseases by 2025 outlined in the WHO global non-communicable disease monitoring framework and a third reduction by 2030 included in the UN Sustainable Development Goals (SDGs).<sup>11,12</sup> Tobacco control has been identified as a crucial and necessary part of reaching these goals, with one in six non-communicable disease-related deaths being attributable to smoking tobacco use.<sup>13–17</sup> As countries work towards meeting global progress targets for reducing the prevalence of smoking tobacco use and premature mortality from non-communicable diseases, timely data on the prevalence of smoking tobacco use and attributable disease are necessary to guide effective policy and planning.<sup>11,17</sup>

The public health significance of smoking tobacco use has resulted in a long tradition of estimating patterns of smoking tobacco use and its health effects.<sup>17–21</sup> Estimates of the attributable burden of smoking tobacco use have been included in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) since its initial publication in 1997.<sup>22</sup> Previous studies estimating the attributable burden of tobacco smoking have combined indirect estimation using the

Smoking Impact Ratio method for cancers and chronic obstructive pulmonary disease, which uses observed lung cancer mortality to indirectly estimate the disease burden attributable to tobacco smoking, with direct estimation using lagged prevalence of daily smoking tobacco use for cardiovascular and circulatory diseases and all other health outcomes.<sup>20,23,24</sup> For health outcomes modelled using daily prevalence, risks among occasional smokers and former smokers were not included, and methods did not reflect well described dose-response associations between smoking intensity and risk of disease. For the health outcomes modelled using the Smoking Impact Ratio method, reliability was low in countries with either scarce or poor quality data on lung cancer mortality and in countries with other important competing risks for lung cancer, such as air pollution.

The objective of this study, which is part of GBD 2019, was to update and improve previous estimates of global trends in the prevalence of tobacco smoking and tobacco smoking-attributable disease for 204 countries and territories, by age and sex, from 1990 to 2019. Using new methods and new data, we aimed to provide novel insights into patterns of smoking intensity and their association with health outcomes that are directly relevant to guiding tobacco control efforts nationally and globally. This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol.

## Methods

### Overview

As part of GBD 2019, we estimated the burden of disease attributable to smoking of tobacco using the comparative risk assessment framework for 204 countries and territories, by age and sex, and from 1990 to 2019. We used direct estimation methods for 36 causally linked health outcomes that show dose-response associations among both current and former smokers. Here, we summarise the key analytical steps: estimating prevalence of current and former use of smoking tobacco; modelling distributions of cigarette-equivalents of tobacco smoked per day, pack-years, and years since cessation; estimating dose-response risk curves for the 36 health outcomes; and calculating population-attributable fractions (PAFs). Full details on each analytical step are provided in appendix 1 (pp 3–28). This study adheres to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).<sup>25</sup>

### Prevalence of smoking tobacco use

We systematically identified and extracted data from 3625 nationally representative surveys, including both multinational and country-specific surveys, covering 200 of the 204 countries and territories included in the analysis. 171 (86%) of 200 countries had at least five surveys for the period 1980–2019, and 141 (71%) countries had data available from 2015 or later. Data for 1980–89 were used to inform time trends, but are not reported in the results. For countries without data, estimates were entirely based on models. We extracted data for individuals aged 10 years and older, and used data on individuals aged 10–14 years to inform model estimates; however, we report prevalence among individuals aged 15 years and older. Additional information on identification of sources, inclusion criteria, and data extraction are in appendix 1 (pp 11–12). A complete list of data sources used in our analysis is available through the Global Health Data Exchange (GHDx).

To ensure that all data included in the model were comparable, and to prevent compositional bias from affecting our estimates, we used two key data processing steps. First, we used linear regression to adjust data from surveys that only reported non-reference case definitions. Our reference case definitions were current use of any smoked tobacco product on a daily or occasional basis, and former use of any smoked tobacco product. We included all smoked tobacco products—eg, cigarettes, pipes, cigars, shisha, bidis, kreteks, and other local smoked tobacco products. We did not include smokeless tobacco, electronic cigarettes (also known as e-cigarettes), vaping products, or heated tobacco products. Risks from chewing tobacco and second-hand smoke are included as other risk factors in GBD and are outside the scope of this study.<sup>1,26</sup>

Second, we split data reported in aggregated age groups or as both sexes combined into our standard

5-year age-sex groups. To estimate an age-sex pattern that reflects observed spatial and temporal variation, we estimated a preliminary prevalence model using only data available in our standard age-sex groups. We then used the estimated age-sex pattern, which varied by location and year, to split aggregated data, a process that also allowed us to propagate uncertainty in the age-sex pattern. These methods have been previously published,<sup>19,20,27</sup> and full details are in appendix 1 (pp 13, 20).

We used spatiotemporal Gaussian process regression (ST-GPR) to model prevalence of both current and former smoking tobacco use (appendix 1 p 21). This modelling approach has been used extensively in GBD to estimate time-varying risk factors.<sup>27,28</sup> Briefly, the model was estimated in three stages. First, the level and trend were set in countries using linear regression based on covariates. Next, the first-stage estimates were adjusted by adding residuals with decaying weights across time, age, and location. Finally, the second-stage estimates were used as the prior in Gaussian process regression, which further refined the model fit and incorporated both data and model uncertainty. 1000 draws from the posterior distribution were retained and used for analysis. We report results with the 95% uncertainty interval (UI) of estimates based on the 2·5th and 97·5th percentile of draws.

### Exposure distribution

Estimates of prevalence of current and former smoking tobacco use define the full population at risk, but risk of disease varies within these groups on the basis of intensity of smoking and length of time since cessation. To incorporate these differences in risk in our estimation framework, we modelled continuous exposure distributions among both current and former smokers. Among current smokers, we estimated two distributions: cross-sectional cigarette-equivalents of tobacco per smoker per day and cumulative pack-years across their lifetime. Among former smokers, we estimated the distribution of the number of years since cessation. To account for heterogeneity in smoked tobacco products, we use a standard unit of cigarette-equivalents of tobacco. We converted non-cigarette tobacco products to cigarette-equivalents on the basis of amount of tobacco (in g), assuming 1 g of tobacco per cigarette. Estimates of cigarette-equivalents consumed per smoker per day combine two sources of information: self-reported smoking patterns from household surveys and supply-side data on country-level consumption available from the Food and Agriculture Organization of the UN (1961–2013), the US Department of Agriculture (1960–2005), and Euromonitor (2002–17). Details on the modelling process for the supply-side data and approach to integrating the two sources of information are in appendix 1 (pp 22–23).

Using estimates of cigarette-equivalents per smoker per day by location, age, and sex from 1960 to 2019,

See Online for appendix 1

For the Global Health Data Exchange see <http://ghdx.healthdata.org/gbd-2019/data-input-sources>

along with estimates of the distribution of initiation age, we reconstructed individual smoking histories on the basis of birth cohort smoking patterns to estimate population-level distributions of pack-years consumed. This approach is crucial to estimation of the burden of health outcomes that are linked to long-term cumulative exposure, because assumptions of constant consumption on the basis of cross-sectional patterns result in underestimation of risk at older ages and overestimation of risk at younger ages.

Where available, we extracted age of cessation or years since cessation from surveys to estimate a distribution of years since cessation among former smokers. Distributions of years since cessation, cigarette-equivalents per smoker per day, and age of initiation were based on an ensemble of underlying distribution shapes, parameterised by means (estimated using ST-GPR) and SDs (predicted from means using linear regression). An expanded description of the ensemble distribution strategy is in appendix 1 (p 24).

### Dose-response risk curves

Previous estimates of smoking-attributable burden in GBD relied on dichotomous exposures, despite well documented dose-response associations. To address this limitation, we estimated dose-response risk curves for both current and former smokers for 36 health outcomes using meta-regression (appendix 1 p 26). This process involved an extensive systematic review, covering 71996 total search string hits, from which 902 prospective cohort and case-control studies were found to be eligible and from which data were extracted (Preferred Reporting Items for Systematic reviews and Meta-Analyses [PRISMA] diagrams for each outcome are in appendix 1 [pp 31–66]). For cancers and chronic obstructive pulmonary disease, we used pack-years as the exposure, allowing risk to reflect both duration and dose (cigarette-equivalents per day) of exposure. For cardiovascular and circulatory diseases and all other health outcomes, we used cigarette-equivalents per smoker per day as the exposure among current smokers, because dose is generally thought to be more important than duration of exposure for these health outcomes. We used the Disease Modelling Ordinary Differential Equation (DisMod ODE) solver to fit non-linear Bayesian meta-regressions for each health outcome.<sup>29,30</sup> Due to a paucity of data on relative risks among individuals younger than 30 years, we attributed outcomes to individuals aged 30 years and older, an approach consistent with previous GBD studies.

Among former smokers, risk decreases with an increasing number of years since cessation, but the level of risk also depends on previous smoking history. To control for differences in smoking history across the populations included in the meta-regressions, we adjusted reported relative risk estimates to standardise the risk at the time of cessation (appendix 1 pp 26–28).<sup>30</sup>

### Population attributable fractions

Inputs to estimation of PAFs included prevalence of current and former smoking tobacco use, continuous exposure distributions, relative risks, and the theoretical minimum risk exposure level. For smoking tobacco use, the theoretical minimum risk exposure level is never smoking. The PAF equation is specified in appendix 1 (p 28). Because the risk reduction curves for former smokers must account for two dimensions—years since cessation and intensity of smoking before cessation—we scaled the risk reduction curves for former smokers to match their starting relative risk (when years since cessation equals zero) to the exposure-weighted relative risk among current smokers in that population. We combined global dose-response risk curves with country-year-age-sex-specific continuous exposure distributions so we could capture differences in risk across countries that result from heterogeneous smoking patterns. Exposures were lagged on the basis of the average length of follow-up across studies included in the meta-regressions (appendix 1 p 28). We calculated attributable burden by multiplying PAFs with cause-specific deaths by location, year, age, and sex, available from GBD 2019.<sup>31</sup> Using the distributive property of PAFs, we also partitioned out smoking-attributable deaths by exposure categories.<sup>32</sup>

Using our PAF estimates, we calculated the number of smoking attributable deaths, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs). We further calculated the ratio of YLLs to YLDs by country and examined associations of this ratio with Socio-demographic Index level. For analyses by country income level, we used World Bank income groups.

We did all analyses using R (versions 3.1–3.6) and Python (version 2.7).

### Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

### Results

Globally, there were 1.14 billion (95% UI 1.13–1.16) current smokers in 2019. Age-standardised prevalence of current use of smoking tobacco among individuals aged 15 years and older was 32.7% (32.3–33.0) among males and 6.62% (6.43–6.83) among females. Age-standardised prevalence among males aged 15 years and older ranged from 7.33% (6.56–8.20) in Peru to 64.6% (62.7–66.6) in Timor-Leste, and among females from 0.696% (0.517–0.906) in Eritrea to 42.3% (36.5–48.4) in Greenland (table). Smoking prevalence exceeded 20% among males in 151 countries and among females in 42 countries (table). Among individuals aged 15 years and older, countries with the highest prevalence of smoking tobacco use among males were mostly in Asia

and Oceania (appendix 2 p 83), whereas countries with the highest prevalence of smoking tobacco use among females were mostly in Europe and Oceania (appendix 2 p 84). Among the 159 countries with a population exceeding 1 million, the highest prevalence of smoking tobacco use in males aged 15 years and older was observed in Timor-Leste, Indonesia, Armenia, Jordan, and Georgia, and the highest prevalence of smoking tobacco use among females aged 15 years and older was observed in Serbia, Chile, Croatia, Bulgaria, and Greece (table). The ten countries with the largest number of tobacco smokers in 2019, together comprising nearly two-thirds of the global tobacco smoking population, were China, India, Indonesia, the USA, Russia, Bangladesh, Japan, Turkey, Vietnam, and the Philippines

(appendix 2 pp 85–93); 341 million (30%) of 1·14 billion tobacco smokers globally lived in China in 2019.

Since 1990, global age-standardised prevalence of smoking tobacco use among males aged 15 years and older decreased by 27·5% (95% UI 26·5–28·5) and among females decreased by 37·7% (35·4–39·9), with variable progress across countries (table). Prevalence of smoking tobacco use among males aged 15 years and older decreased significantly between 1990 and 2019 in 135 countries (66%), but decreased significantly among females in only 68 countries (33%). The largest decreases were observed in Brazil, where prevalence decreased by 72·5% (70·1–74·7) among males and by 74·7% (71·2–78·0) among females. Among individuals aged 15 years and older, prevalence of smoking tobacco use

See Online for appendix 2

	Age-standardised prevalence, 2019		Percentage change, 1990–2019	
	Females	Males	Females	Males
<b>Global</b>	<b>6·62 (6·43 to 6·83)</b>	<b>32·7 (32·3 to 33·0)</b>	<b>–37·7 (–39·9 to –35·4)</b>	<b>–27·5 (–28·5 to –26·5)</b>
<b>Central Europe, eastern Europe, and central Asia</b>	<b>15·5 (14·9 to 16·2)</b>	<b>39·5 (38·9 to 40·0)</b>	<b>–4·37 (–10·2 to 2·00)</b>	<b>–21·6 (–23·2 to –20·0)</b>
Central Asia	3·79 (3·45 to 4·18)	34·3 (33·5 to 35·1)	–5·97 (–19·7 to 7·78)	–12·3 (–15·1 to –9·61)
Armenia	3·10 (2·48 to 3·79)	55·3 (53·6 to 57·0)	–5·19 (–33·9 to 35·0)	–8·42 (–13·1 to –3·89)
Azerbaijan	2·50 (1·86 to 3·30)	43·6 (41·9 to 45·2)	30·8 (–13·7 to 91·7)	–1·55 (–8·50 to 5·78)
Georgia	7·03 (5·97 to 8·15)	51·8 (50·0 to 53·6)	11·3 (–16·7 to 45·2)	5·80 (–0·933 to 13·6)
Kazakhstan	7·69 (6·46 to 9·16)	43·2 (41·3 to 45·0)	2·88 (–25·3 to 33·1)	–14·9 (–19·9 to –10·0)
Kyrgyzstan	4·65 (3·77 to 5·63)	43·6 (41·7 to 45·5)	49·0 (7·52 to 105)	–5·39 (–10·5 to –0·251)
Mongolia	8·26 (6·86 to 9·84)	51·7 (49·6 to 53·9)	44·4 (7·67 to 88·9)	11·0 (4·24 to 18·5)
Tajikistan	1·29 (0·982 to 1·68)	16·9 (15·7 to 18·3)	–41·7 (–61·7 to –15·0)	–45·8 (–51·7 to –39·4)
Turkmenistan	3·05 (2·34 to 3·91)	21·6 (19·8 to 23·4)	–37·4 (–58·3 to –9·91)	–46·5 (–52·2 to –40·4)
Uzbekistan	1·94 (1·48 to 2·48)	24·8 (23·1 to 26·6)	47·9 (–0·335 to 117)	36·3 (19·6 to 53·5)
Central Europe	25·9 (25·0 to 26·7)	35·8 (35·1 to 36·4)	–8·47 (–13·0 to –3·96)	–24·7 (–26·5 to –22·8)
Albania	11·9 (9·87 to 14·2)	51·5 (49·7 to 53·1)	85·0 (35·1 to 145)	25·4 (16·5 to 34·3)
Bosnia and Herzegovina	30·5 (26·8 to 34·2)	45·1 (42·6 to 47·5)	41·1 (16·1 to 70·3)	17·5 (7·49 to 27·7)
Bulgaria	32·5 (29·5 to 35·4)	42·5 (40·4 to 44·6)	–16·2 (–29·5 to –0·400)	–20·4 (–26·0 to –14·9)
Croatia	32·6 (29·9 to 35·5)	39·1 (37·2 to 41·0)	–11·7 (–23·5 to 0·755)	–17·6 (–23·3 to –11·8)
Czech Republic	23·2 (21·3 to 25·2)	34·1 (32·5 to 35·6)	–20·2 (–29·1 to –9·61)	–21·7 (–27·5 to –15·9)
Hungary	26·5 (23·8 to 29·2)	34·2 (32·0 to 36·1)	–18·4 (–29·4 to –6·32)	–21·7 (–27·2 to –15·6)
Montenegro	32·7 (30·3 to 35·2)	37·5 (35·7 to 39·3)	0·505 (–15·8 to 20·0)	–8·35 (–16·0 to –0·294)
North Macedonia	31·0 (28·3 to 33·9)	47·1 (45·0 to 49·2)	4·38 (–14·7 to 25·1)	–2·24 (–9·31 to 5·48)
Poland	24·4 (22·5 to 26·3)	31·8 (30·4 to 33·3)	–17·8 (–25·8 to –9·17)	–40·5 (–43·6 to –37·2)
Romania	23·5 (21·7 to 25·5)	38·4 (36·8 to 40·0)	8·91 (–5·85 to 25·1)	–18·8 (–24·7 to –12·8)
Serbia	37·8 (34·5 to 41·1)	38·8 (36·9 to 40·8)	20·3 (2·25 to 39·8)	–6·30 (–13·4 to 1·34)
Slovakia	20·9 (18·7 to 23·3)	33·3 (31·2 to 35·3)	–14·9 (–31·4 to 4·94)	–23·3 (–30·0 to –16·2)
Slovenia	24·9 (22·6 to 27·4)	29·8 (28·0 to 31·5)	9·05 (–11·3 to 30·7)	–11·0 (–19·1 to –1·45)
Eastern Europe	15·6 (14·4 to 17·0)	44·7 (43·7 to 45·8)	15·9 (2·24 to 31·3)	–19·4 (–22·0 to –16·8)
Belarus	23·6 (20·7 to 26·6)	50·2 (47·9 to 52·5)	31·5 (0·570 to 69·1)	–5·15 (–11·8 to 1·42)
Estonia	18·9 (17·2 to 20·7)	31·7 (30·2 to 33·1)	–12·9 (–24·8 to –1·42)	–28·3 (–32·5 to –23·9)
Latvia	21·3 (19·3 to 23·4)	46·9 (45·2 to 48·7)	–3·33 (–18·8 to 15·5)	–12·9 (–17·4 to –7·98)
Lithuania	20·3 (18·4 to 22·6)	37·9 (36·1 to 39·8)	28·9 (10·4 to 50·4)	–18·5 (–23·9 to –12·9)
Moldova	7·20 (5·93 to 8·68)	40·6 (38·6 to 42·7)	11·7 (–17·2 to 47·7)	3·88 (–4·24 to 13·0)
Russia	15·5 (13·9 to 17·3)	45·6 (44·1 to 47·0)	26·1 (5·67 to 49·7)	–17·6 (–21·1 to –13·9)
Ukraine	14·4 (12·7 to 16·3)	42·0 (40·3 to 43·6)	–7·85 (–26·0 to 12·4)	–28·3 (–32·1 to –24·4)

(Table continues on next page)



	Age-standardised prevalence, 2019		Percentage change 1990–2019	
	Females	Males	Females	Males
(Continued from previous page)				
<b>High income</b>	<b>17.6 (17.1 to 18.2)</b>	<b>26.9 (26.4 to 27.3)</b>	<b>–28.8 (–31.2 to –26.2)</b>	<b>–32.2 (–33.4 to –31.0)</b>
Australasia	14.5 (12.7 to 16.5)	16.7 (15.6 to 17.9)	–46.5 (–53.1 to –39.0)	–46.2 (–50.0 to –42.3)
Australia	14.4 (12.2 to 16.7)	16.4 (15.1 to 17.8)	–46.8 (–54.9 to –38.0)	–48.1 (–52.4 to –43.7)
New Zealand	15.2 (13.9 to 16.5)	18.4 (17.5 to 19.4)	–44.8 (–49.8 to –39.5)	–35.6 (–39.5 to –31.4)
High-income Asia Pacific	8.48 (7.48 to 9.64)	35.9 (34.4 to 37.3)	–25.6 (–35.7 to –14.7)	–36.9 (–39.7 to –34.0)
Brunei	5.39 (4.28 to 6.78)	28.5 (26.1 to 31.2)	–31.3 (–50.9 to –7.75)	–33.3 (–40.4 to –25.8)
Japan	10.2 (8.71 to 11.9)	33.4 (31.4 to 35.5)	–23.6 (–35.2 to –9.65)	–41.7 (–45.3 to –38.0)
Singapore	6.82 (5.38 to 8.41)	20.6 (18.9 to 22.4)	–32.6 (–52.1 to –8.90)	–31.3 (–39.6 to –22.5)
South Korea	5.21 (4.14 to 6.58)	42.5 (40.1 to 44.7)	–18.4 (–42.8 to 11.5)	–25.2 (–30.4 to –19.5)
High-income North America	15.3 (14.1 to 16.7)	19.7 (18.8 to 20.7)	–39.9 (–44.8 to –34.5)	–31.8 (–35.3 to –28.2)
Canada	15.9 (13.4 to 18.6)	18.3 (16.8 to 19.8)	–48.2 (–56.5 to –38.9)	–46.8 (–51.7 to –42.0)
Greenland	42.3 (36.5 to 48.4)	44.1 (40.9 to 47.3)	–5.32 (–21.0 to 13.6)	–10.2 (–18.0 to –2.05)
USA	15.3 (13.9 to 16.7)	19.9 (18.8 to 21.0)	–38.7 (–44.2 to –32.7)	–29.8 (–33.7 to –25.7)
Southern Latin America	23.3 (21.2 to 25.3)	31.3 (29.9 to 32.7)	–20.0 (–31.2 to –8.02)	–17.2 (–22.8 to –11.3)
Argentina	19.6 (17.3 to 22.2)	29.2 (27.4 to 31.0)	–22.6 (–37.9 to –4.07)	–17.5 (–25.7 to –7.94)
Chile	32.7 (28.7 to 36.6)	36.2 (33.9 to 38.4)	–12.7 (–27.0 to 4.89)	–13.0 (–20.6 to –4.91)
Uruguay	23.1 (19.4 to 26.7)	31.0 (28.8 to 33.3)	–18.1 (–33.7 to –0.553)	–23.0 (–30.0 to –14.8)
Western Europe	22.7 (22.0 to 23.4)	28.8 (28.2 to 29.3)	–24.2 (–26.7 to –21.8)	–28.8 (–30.2 to –27.4)
Andorra	24.4 (19.6 to 29.5)	31.4 (28.6 to 34.2)	–19.8 (–37.9 to 1.56)	–25.2 (–32.8 to –17.2)
Austria	26.1 (23.4 to 29.0)	36.1 (34.0 to 38.3)	–10.5 (–20.2 to 0.384)	–14.2 (–19.9 to –8.34)
Belgium	21.4 (19.6 to 23.3)	24.9 (23.6 to 26.2)	–28.5 (–35.6 to –21.1)	–39.3 (–43.1 to –35.6)
Cyprus	21.3 (18.7 to 24.3)	44.8 (42.6 to 47.1)	–11.6 (–30.8 to 9.57)	–5.43 (–12.5 to 2.85)
Denmark	22.6 (20.6 to 24.8)	22.7 (21.3 to 24.1)	–49.5 (–54.0 to –44.4)	–49.2 (–52.3 to –45.7)
Finland	18.1 (16.3 to 20.3)	24.8 (23.3 to 26.2)	–31.2 (–39.3 to –21.5)	–27.9 (–32.3 to –23.2)
France	31.3 (28.8 to 33.9)	36.9 (35.1 to 38.6)	–1.18 (–9.35 to 7.54)	–17.2 (–21.4 to –12.9)
Germany	23.0 (21.1 to 24.9)	29.9 (28.4 to 31.4)	–18.0 (–25.2 to –10.3)	–20.7 (–25.2 to –16.2)
Greece	32.2 (29.5 to 35.1)	44.1 (42.3 to 46.1)	–0.620 (–9.99 to 8.67)	–18.4 (–22.2 to –14.5)
Iceland	15.1 (13.1 to 17.5)	15.8 (14.7 to 17.1)	–47.7 (–56.6 to –37.8)	–51.4 (–55.8 to –46.3)
Ireland	22.8 (20.4 to 25.3)	21.9 (20.2 to 23.6)	–27.8 (–35.7 to –19.6)	–38.7 (–43.8 to –33.7)
Israel	14.9 (12.8 to 17.2)	26.4 (24.6 to 28.3)	–39.8 (–51.2 to –27.4)	–33.8 (–39.7 to –27.9)
Italy	18.9 (17.3 to 20.6)	27.3 (25.8 to 28.8)	–28.1 (–34.5 to –21.2)	–30.5 (–34.6 to –26.3)
Luxembourg	21.3 (19.3 to 23.3)	26.2 (24.5 to 28.0)	–27.9 (–36.3 to –19.1)	–31.6 (–36.8 to –25.4)
Malta	22.0 (19.2 to 24.9)	26.9 (24.9 to 28.8)	–15.0 (–30.9 to 2.21)	–36.0 (–41.9 to –29.5)
Monaco	23.6 (18.9 to 28.6)	29.0 (26.4 to 31.7)	–19.5 (–38.7 to 2.21)	–24.9 (–32.9 to –15.7)
Netherlands	20.4 (18.6 to 22.2)	25.0 (23.6 to 26.4)	–46.8 (–51.7 to –41.5)	–42.4 (–46.0 to –38.9)
Norway	16.5 (14.3 to 18.9)	20.2 (18.7 to 22.0)	–57.6 (–63.9 to –50.4)	–49.8 (–54.4 to –44.9)
Portugal	22.4 (20.2 to 24.7)	33.4 (31.7 to 35.0)	30.6 (16.4 to 45.4)	–18.7 (–23.1 to –14.2)
San Marino	18.1 (15.2 to 21.5)	21.6 (19.7 to 23.4)	–36.0 (–50.7 to –18.3)	–40.5 (–47.3 to –33.4)
Spain	24.6 (22.6 to 26.8)	30.7 (29.1 to 32.5)	–23.6 (–30.2 to –16.3)	–39.6 (–42.9 to –36.0)
Sweden	14.4 (12.6 to 16.5)	12.4 (11.3 to 13.5)	–47.1 (–54.5 to –38.7)	–44.6 (–50.0 to –38.8)
Switzerland	23.4 (20.7 to 26.3)	29.3 (27.2 to 31.2)	–18.9 (–28.6 to –8.35)	–23.5 (–28.6 to –18.4)
UK	18.1 (16.3 to 19.9)	21.7 (20.4 to 22.9)	–42.5 (–48.4 to –36.6)	–35.7 (–39.7 to –32.0)
<b>Latin America and Caribbean</b>	<b>7.64 (7.16 to 8.10)</b>	<b>17.1 (16.6 to 17.5)</b>	<b>–59.6 (–62.5 to –56.5)</b>	<b>–52.3 (–53.9 to –50.6)</b>
Andean Latin America	4.84 (4.25 to 5.48)	14.0 (13.3 to 14.6)	–17.4 (–33.4 to 0.994)	–16.9 (–23.1 to –10.5)
Bolivia	7.31 (5.94 to 8.85)	18.2 (16.8 to 19.7)	–0.326 (–29.1 to 36.6)	–7.58 (–18.9 to 5.09)
Ecuador	4.97 (4.14 to 5.98)	24.7 (23.5 to 25.9)	–18.1 (–38.7 to 7.54)	–8.37 (–17.2 to 0.777)
Peru	4.02 (3.22 to 4.95)	7.33 (6.56 to 8.20)	–23.2 (–47.1 to 9.24)	–35.4 (–45.4 to –24.6)

(Table continues on next page)

	Age-standardised prevalence, 2019		Percentage change 1990–2019	
	Females	Males	Females	Males
(Continued from previous page)				
Caribbean	8.65 (7.76 to 9.55)	19.6 (18.9 to 20.4)	–37.1 (–45.9 to –26.9)	–30.9 (–34.6 to –27.0)
Antigua and Barbuda	5.56 (4.29 to 6.97)	12.5 (11.1 to 14.1)	31.5 (–6.42 to 81.9)	31.4 (11.8 to 52.7)
The Bahamas	3.18 (2.51 to 4.04)	11.4 (10.4 to 12.6)	–11.4 (–38.4 to 27.1)	–0.304 (–13.6 to 15.5)
Barbados	4.61 (3.60 to 5.88)	13.9 (12.6 to 15.5)	–3.25 (–34.2 to 38.0)	–15.4 (–26.6 to –2.65)
Belize	4.13 (3.18 to 5.24)	22.5 (20.4 to 24.6)	9.24 (–25.9 to 50.3)	1.95 (–11.1 to 15.7)
Bermuda	8.32 (6.80 to 10.2)	18.1 (16.5 to 19.9)	–2.45 (–28.8 to 33.4)	–0.776 (–13.6 to 14.7)
Cuba	15.3 (12.7 to 17.9)	31.8 (29.4 to 34.4)	–34.2 (–49.2 to –15.1)	–25.9 (–32.8 to –18.2)
Dominica	6.29 (4.82 to 8.04)	15.1 (13.4 to 16.8)	–6.88 (–35.3 to 27.5)	–2.73 (–17.0 to 13.5)
Dominican Republic	9.27 (7.70 to 10.9)	13.7 (12.6 to 14.9)	–21.0 (–39.6 to 1.18)	–7.15 (–18.0 to 5.97)
Grenada	5.39 (4.16 to 6.85)	17.7 (15.8 to 19.6)	2.67 (–30.5 to 44.3)	7.33 (–7.82 to 23.7)
Guyana	4.20 (3.32 to 5.19)	24.9 (23.3 to 26.8)	–9.62 (–36.7 to 22.6)	6.45 (–6.41 to 20.9)
Haiti	2.65 (2.05 to 3.36)	10.1 (9.22 to 11.0)	–48.6 (–65.2 to –27.5)	–45.8 (–52.6 to –38.4)
Jamaica	6.82 (5.73 to 8.09)	20.1 (18.5 to 21.8)	–21.8 (–40.1 to 0.233)	–26.5 (–34.8 to –17.5)
Puerto Rico	8.57 (7.42 to 9.87)	16.0 (14.9 to 17.2)	–14.2 (–31.8 to 6.44)	–18.3 (–26.4 to –8.88)
Saint Kitts and Nevis	2.87 (2.16 to 3.75)	10.5 (9.30 to 11.8)	–0.0613 (–32.4 to 41.3)	1.56 (–15.0 to 20.1)
Saint Lucia	5.27 (4.17 to 6.49)	19.2 (17.4 to 21.1)	–14.2 (–39.3 to 18.3)	–13.3 (–24.0 to –0.879)
Saint Vincent and the Grenadines	4.24 (3.22 to 5.53)	20.3 (18.5 to 22.1)	2.04 (–28.9 to 41.4)	–4.93 (–15.8 to 7.45)
Suriname	8.85 (7.07 to 11.0)	34.2 (31.7 to 36.6)	–25.5 (–46.9 to 0.950)	–17.7 (–25.5 to –8.96)
Trinidad and Tobago	8.17 (6.44 to 10.1)	28.9 (26.6 to 31.2)	–7.88 (–34.0 to 26.3)	–12.7 (–22.4 to –2.34)
Virgin Islands	4.98 (3.98 to 6.18)	8.28 (7.38 to 9.22)	–24.3 (–46.3 to 2.89)	–23.3 (–34.3 to –9.97)
Central Latin America	8.72 (8.04 to 9.48)	22.7 (22.0 to 23.4)	–42.2 (–49.0 to –34.4)	–40.1 (–42.6 to –37.5)
Colombia	9.71 (8.42 to 11.2)	14.7 (13.6 to 15.9)	–33.3 (–49.3 to –13.6)	–53.6 (–58.7 to –48.1)
Costa Rica	7.19 (5.93 to 8.67)	15.3 (14.1 to 16.6)	–48.2 (–60.7 to –32.1)	–45.9 (–52.2 to –38.8)
El Salvador	3.70 (2.91 to 4.63)	17.3 (15.8 to 18.9)	36.9 (–5.05 to 87.8)	34.3 (15.4 to 55.2)
Guatemala	4.34 (3.43 to 5.41)	20.5 (19.0 to 22.0)	–5.00 (–32.1 to 29.7)	–14.6 (–24.8 to –4.31)
Honduras	5.25 (4.15 to 6.61)	24.0 (22.2 to 25.9)	–11.8 (–35.3 to 16.4)	–19.9 (–28.4 to –10.5)
Mexico	9.01 (7.79 to 10.3)	27.0 (25.7 to 28.2)	–48.1 (–57.1 to –38.3)	–40.6 (–44.3 to –36.8)
Nicaragua	5.46 (4.15 to 7.01)	21.5 (19.5 to 23.7)	–16.2 (–42.4 to 17.4)	–23.3 (–33.2 to –12.7)
Panama	4.57 (3.58 to 5.71)	12.4 (11.3 to 13.7)	–35.9 (–54.5 to –10.6)	–39.1 (–46.3 to –31.1)
Venezuela	11.7 (9.37 to 14.5)	22.8 (20.5 to 25.2)	–32.2 (–49.8 to –11.0)	–35.3 (–42.6 to –27.0)
Tropical Latin America	6.90 (6.06 to 7.74)	11.2 (10.6 to 11.9)	–74.3 (–77.6 to –70.8)	–71.5 (–73.7 to –69.2)
Brazil	6.86 (6.02 to 7.73)	10.9 (10.1 to 11.6)	–74.7 (–78.0 to –71.2)	–72.5 (–74.7 to –70.1)
Paraguay	8.33 (6.79 to 10.1)	24.6 (22.7 to 26.7)	–41.9 (–56.4 to –24.7)	–39.7 (–46.3 to –33.4)
<b>North Africa and Middle East</b>	<b>5.63 (5.31 to 5.99)</b>	<b>32.4 (31.9 to 32.9)</b>	<b>–2.88 (–12.7 to 7.23)</b>	<b>–11.2 (–13.6 to –8.75)</b>
Afghanistan	2.67 (2.10 to 3.39)	17.0 (15.7 to 18.4)	179 (93.4 to 285)	205 (158 to 254)
Algeria	1.74 (1.34 to 2.24)	32.7 (30.6 to 34.8)	–28.7 (–51.5 to –0.699)	–7.01 (–16.2 to 2.31)
Bahrain	5.10 (4.13 to 6.33)	23.4 (21.4 to 25.5)	–20.7 (–40.4 to 2.68)	–1.03 (–11.1 to 10.0)
Egypt	1.06 (0.803 to 1.37)	43.4 (42.2 to 44.7)	2.41 (–31.7 to 50.5)	13.1 (4.88 to 21.9)
Iran	4.73 (3.84 to 5.75)	24.9 (23.2 to 26.5)	8.28 (–26.7 to 47.9)	2.30 (–8.74 to 14.6)
Iraq	3.53 (2.81 to 4.38)	37.6 (35.4 to 39.6)	–22.1 (–45.0 to 6.51)	–18.8 (–25.2 to –11.5)
Jordan	11.8 (10.1 to 13.8)	53.0 (51.5 to 54.5)	10.6 (–15.8 to 44.6)	11.4 (4.64 to 18.3)
Kuwait	4.72 (3.78 to 5.76)	33.7 (31.5 to 35.8)	–8.57 (–36.3 to 24.3)	–14.2 (–21.6 to –6.18)
Lebanon	26.0 (22.8 to 29.0)	46.1 (44.0 to 48.2)	45.1 (15.8 to 80.2)	25.1 (14.4 to 36.5)
Libya	1.46 (1.10 to 1.94)	38.6 (36.3 to 41.0)	–2.10 (–34.2 to 38.4)	0.602 (–8.37 to 10.7)
Morocco	1.06 (0.788 to 1.42)	22.5 (20.9 to 24.1)	–31.3 (–54.3 to 1.02)	–33.2 (–39.3 to –26.1)
Oman	1.88 (1.45 to 2.43)	15.8 (14.5 to 17.3)	–11.0 (–37.4 to 23.1)	–24.6 (–32.4 to –16.5)
Palestine	3.89 (3.07 to 4.84)	40.8 (38.6 to 43.2)	–3.23 (–29.4 to 28.9)	–8.48 (–14.7 to –2.05)
Qatar	2.97 (2.24 to 3.94)	21.9 (20.3 to 23.6)	4.14 (–32.9 to 54.7)	–4.13 (–15.4 to 8.50)
Saudi Arabia	2.17 (1.69 to 2.71)	22.6 (21.1 to 24.0)	45.3 (0.241 to 99.6)	39.0 (26.2 to 53.6)

(Table continues on next page)

	Age-standardised prevalence, 2019		Percentage change 1990–2019	
	Females	Males	Females	Males
(Continued from previous page)				
Sudan	1.95 (1.46 to 2.54)	19.5 (18.0 to 21.1)	–15.2 (–42.5 to 23.4)	–12.3 (–22.9 to –0.539)
Syria	6.20 (4.77 to 7.97)	41.9 (39.0 to 44.8)	–23.3 (–47.1 to 6.07)	–16.5 (–23.3 to –9.84)
Tunisia	2.70 (2.12 to 3.45)	45.4 (43.2 to 47.7)	–19.9 (–43.5 to 10.8)	–11.1 (–17.0 to –4.99)
Turkey	18.4 (16.6 to 20.3)	43.2 (41.6 to 44.9)	14.6 (–3.48 to 33.5)	–21.8 (–26.3 to –17.2)
United Arab Emirates	3.79 (2.96 to 4.81)	17.9 (16.5 to 19.3)	2.58 (–27.0 to 44.1)	–21.0 (–30.5 to –10.8)
Yemen	8.90 (7.46 to 10.7)	31.5 (29.5 to 33.6)	4.41 (–24.0 to 40.2)	–4.64 (–14.1 to 5.27)
<b>South Asia</b>	<b>3.26 (2.83 to 3.78)</b>	<b>25.2 (24.2 to 26.2)</b>	<b>–34.1 (–45.8 to –21.1)</b>	<b>–37.8 (–40.4 to –35.1)</b>
Bangladesh	2.13 (1.68 to 2.66)	44.9 (43.0 to 47.0)	–27.9 (–47.7 to –4.36)	–11.4 (–16.7 to –6.25)
Bhutan	4.80 (3.79 to 5.95)	14.8 (13.4 to 16.2)	–4.62 (–33.8 to 31.6)	–12.9 (–24.1 to –0.228)
India	3.10 (2.59 to 3.74)	23.0 (21.9 to 24.2)	–31.2 (–46.6 to –12.9)	–41.0 (–44.2 to –37.6)
Nepal	13.6 (11.9 to 15.6)	31.4 (29.8 to 33.0)	–54.0 (–61.9 to –44.6)	–37.0 (–41.4 to –32.6)
Pakistan	3.77 (3.05 to 4.65)	24.7 (23.3 to 26.3)	–40.7 (–58.0 to –18.0)	–39.2 (–44.3 to –33.6)
<b>Southeast Asia, east Asia, and Oceania</b>	<b>3.94 (3.51 to 4.39)</b>	<b>49.4 (48.4 to 50.4)</b>	<b>–22.1 (–33.2 to –11.0)</b>	<b>–16.6 (–18.6 to –14.5)</b>
East Asia	3.57 (2.97 to 4.18)	49.5 (48.0 to 50.8)	–20.7 (–36.4 to –3.84)	–18.1 (–20.8 to –15.4)
China	3.54 (2.91 to 4.18)	49.7 (48.3 to 51.1)	–20.9 (–37.4 to –3.53)	–18.2 (–21.0 to –15.5)
North Korea	4.48 (3.57 to 5.69)	43.6 (41.3 to 45.6)	11.6 (–20.7 to 51.2)	–8.47 (–15.3 to –0.989)
Taiwan (Province of China)	4.98 (3.94 to 6.21)	39.6 (37.5 to 41.7)	–27.9 (–51.0 to –0.968)	–18.2 (–24.3 to –11.5)
Oceania	18.0 (16.0 to 20.2)	41.3 (39.4 to 43.2)	–17.7 (–32.1 to –1.23)	–14.9 (–19.7 to –9.54)
American Samoa	22.4 (18.3 to 27.2)	42.1 (39.2 to 45.2)	–4.19 (–27.7 to 25.2)	–4.14 (–12.7 to 5.48)
Cook Islands	24.2 (20.5 to 28.6)	36.7 (34.4 to 39.1)	–0.774 (–21.8 to 25.9)	–9.81 (–18.7 to –0.276)
Federated States of Micronesia	36.4 (31.0 to 41.5)	62.2 (59.7 to 64.8)	12.4 (–9.52 to 35.5)	3.73 (–2.38 to 9.83)
Fiji	14.5 (12.0 to 17.3)	42.5 (40.0 to 45.4)	–18.9 (–38.4 to 6.27)	–14.8 (–21.6 to –7.97)
Guam	20.1 (17.8 to 22.3)	30.3 (28.6 to 32.1)	–8.28 (–26.4 to 12.2)	–14.6 (–22.4 to –6.08)
Kiribati	35.1 (31.5 to 38.6)	63.8 (61.7 to 65.9)	0.681 (–16.7 to 21.3)	6.98 (0.976 to 13.2)
Marshall Islands	9.75 (7.74 to 12.0)	35.0 (32.3 to 37.5)	27.1 (–9.19 to 75.7)	3.09 (–7.84 to 15.3)
Nauru	40.3 (36.3 to 44.6)	43.3 (40.9 to 45.8)	–7.17 (–22.1 to 9.84)	–4.09 (–11.8 to 4.43)
Niue	15.8 (13.1 to 18.8)	27.0 (25.0 to 29.1)	–1.31 (–26.2 to 32.3)	–7.53 (–17.6 to 3.99)
Northern Mariana Islands	18.0 (14.3 to 22.1)	41.0 (38.0 to 43.9)	–17.7 (–37.6 to 8.84)	–13.1 (–21.1 to –4.45)
Palau	12.6 (10.9 to 14.5)	32.4 (30.6 to 34.3)	–1.96 (–25.5 to 25.2)	–6.71 (–15.4 to 3.12)
Papua New Guinea	18.4 (15.8 to 21.3)	40.2 (37.7 to 42.6)	–21.2 (–38.7 to 0.844)	–17.3 (–23.9 to –10.2)
Samoa	14.5 (12.5 to 16.6)	39.4 (37.2 to 41.6)	–11.6 (–32.5 to 13.1)	–11.4 (–18.4 to –4.35)
Solomon Islands	19.3 (17.0 to 21.8)	52.2 (49.9 to 54.2)	7.00 (–16.4 to 36.0)	3.90 (–2.92 to 11.7)
Tokelau	16.6 (13.0 to 20.6)	39.6 (36.4 to 42.5)	0.116 (–26.1 to 31.5)	–5.30 (–14.4 to 5.05)
Tonga	13.3 (11.3 to 15.4)	42.5 (40.2 to 44.8)	–1.21 (–20.6 to 22.1)	–22.3 (–27.0 to –17.2)
Tuvalu	20.7 (17.3 to 24.4)	45.4 (42.6 to 48.0)	9.73 (–17.7 to 43.3)	3.49 (–4.63 to 13.0)
Vanuatu	5.70 (4.54 to 6.95)	38.2 (36.0 to 40.3)	–17.8 (–43.4 to 14.2)	–11.8 (–19.4 to –3.90)
Southeast Asia	4.51 (4.18 to 4.87)	48.2 (47.5 to 48.9)	–29.9 (–37.0 to –22.0)	–12.6 (–14.4 to –10.7)
Cambodia	5.09 (4.17 to 6.10)	40.6 (38.8 to 42.3)	–13.9 (–34.6 to 10.6)	–19.7 (–24.3 to –14.7)
Indonesia	3.60 (3.00 to 4.31)	58.3 (57.0 to 59.6)	7.99 (–17.2 to 39.2)	6.94 (3.14 to 10.6)
Laos	6.98 (5.73 to 8.29)	49.1 (46.8 to 51.2)	29.3 (–6.25 to 71.2)	9.06 (1.05 to 17.2)
Malaysia	3.20 (2.57 to 3.92)	40.3 (38.1 to 42.3)	–26.0 (–47.5 to 1.04)	–22.3 (–28.1 to –16.0)
Maldives	7.35 (5.88 to 9.03)	46.5 (43.8 to 48.9)	–6.48 (–32.8 to 23.8)	–6.02 (–13.3 to 0.792)
Mauritius	5.40 (4.36 to 6.60)	41.2 (39.2 to 43.3)	–7.65 (–32.1 to 23.3)	–13.0 (–19.2 to –6.93)
Myanmar	8.59 (7.24 to 10.0)	41.0 (39.2 to 42.8)	–48.7 (–59.6 to –35.3)	–32.2 (–36.6 to –27.8)
Philippines	8.24 (7.24 to 9.31)	40.9 (39.3 to 42.5)	–37.7 (–50.7 to –22.6)	–28.9 (–32.9 to –24.6)
Seychelles	7.01 (5.58 to 8.62)	39.7 (36.9 to 42.4)	–5.93 (–34.0 to 30.1)	–10.9 (–19.7 to –1.99)
Sri Lanka	1.80 (1.39 to 2.26)	30.1 (28.5 to 31.8)	–40.7 (–58.4 to –17.4)	–30.8 (–36.0 to –24.9)

(Table continues on next page)




	Age-standardised prevalence, 2019		Percentage change 1990–2019	
	Females	Males	Females	Males
(Continued from previous page)				
Thailand	3.49 (2.89 to 4.19)	39.8 (38.5 to 41.3)	–46.5 (–59.9 to –31.5)	–25.5 (–29.4 to –21.5)
Timor-Leste	5.15 (4.18 to 6.21)	64.6 (62.7 to 66.6)	–4.15 (–30.1 to 26.9)	1.49 (–3.55 to 6.71)
Vietnam	2.68 (2.13 to 3.30)	47.1 (45.3 to 48.8)	–32.9 (–50.2 to –13.4)	–20.3 (–24.2 to –16.3)
<b>Sub-Saharan Africa</b>	<b>2.94 (2.78 to 3.10)</b>	<b>17.5 (17.2 to 17.9)</b>	<b>–34.1 (–39.1 to –28.9)</b>	<b>–22.8 (–24.7 to –20.6)</b>
Central sub-Saharan Africa	1.74 (1.46 to 2.06)	20.7 (19.6 to 22.0)	–4.72 (–26.1 to 18.9)	–6.47 (–14.6 to 1.85)
Angola	2.74 (2.14 to 3.51)	18.7 (17.2 to 20.2)	–9.87 (–36.6 to 23.5)	–13.2 (–23.3 to –1.61)
Central African Republic	1.60 (1.22 to 2.12)	15.0 (13.3 to 16.8)	–26.1 (–50.2 to 4.37)	–25.8 (–36.0 to –15.1)
Congo (Brazzaville)	1.81 (1.33 to 2.42)	20.7 (19.0 to 22.6)	20.3 (–24.1 to 75.6)	28.8 (13.7 to 47.7)
Democratic Republic of the Congo	1.36 (1.01 to 1.79)	21.6 (20.0 to 23.4)	–6.49 (–38.2 to 34.9)	–5.93 (–17.1 to 5.72)
Equatorial Guinea	2.50 (1.81 to 3.47)	27.5 (25.0 to 29.8)	4.27 (–36.2 to 58.2)	1.93 (–10.7 to 15.7)
Gabon	3.55 (2.71 to 4.54)	21.9 (20.3 to 23.7)	26.1 (–17.1 to 84.3)	17.3 (1.42 to 35.2)
Eastern sub-Saharan Africa	3.14 (2.93 to 3.37)	17.6 (17.1 to 18.0)	–18.6 (–26.5 to –9.69)	–23.7 (–26.4 to –20.4)
Burundi	4.23 (3.38 to 5.28)	16.3 (15.1 to 17.5)	–31.9 (–52.9 to –4.28)	–36.3 (–43.5 to –28.5)
Comoros	2.99 (2.31 to 3.76)	23.3 (21.5 to 25.1)	–6.26 (–35.1 to 35.3)	–15.6 (–25.0 to –5.67)
Djibouti	5.52 (4.36 to 6.90)	42.2 (39.6 to 44.9)	14.4 (–18.8 to 61.1)	15.9 (5.62 to 27.6)
Eritrea	0.696 (0.517 to 0.906)	12.5 (11.2 to 13.9)	–20.8 (–48.8 to 13.5)	–21.9 (–33.4 to –8.83)
Ethiopia	1.31 (1.01 to 1.69)	10.5 (9.60 to 11.4)	–3.30 (–33.3 to 37.1)	–15.5 (–26.7 to –2.48)
Kenya	2.52 (2.00 to 3.20)	19.2 (17.8 to 20.4)	–35.2 (–54.4 to –9.94)	–35.8 (–42.2 to –28.8)
Madagascar	2.57 (2.00 to 3.30)	24.9 (22.9 to 26.8)	–40.1 (–57.7 to –16.5)	–37.7 (–44.0 to –30.9)
Malawi	3.11 (2.44 to 3.93)	24.0 (22.6 to 25.4)	–15.5 (–41.7 to 17.6)	–0.233 (–9.99 to 10.1)
Mozambique	5.94 (4.68 to 7.39)	23.6 (21.6 to 25.7)	–7.30 (–34.1 to 27.9)	–5.52 (–17.2 to 6.57)
Rwanda	8.51 (7.00 to 10.1)	21.7 (20.4 to 23.2)	–1.82 (–26.1 to 29.3)	–1.51 (–12.1 to 10.9)
Somalia	2.82 (2.17 to 3.66)	20.5 (18.3 to 22.7)	–17.9 (–43.1 to 12.0)	–15.7 (–26.9 to –4.18)
South Sudan	2.71 (2.05 to 3.43)	20.6 (18.5 to 22.8)	–18.4 (–42.3 to 9.34)	–17.7 (–28.2 to –7.07)
Uganda	4.18 (3.43 to 5.02)	14.6 (13.6 to 15.6)	–1.00 (–26.2 to 31.2)	–24.0 (–32.4 to –15.0)
Tanzania	2.96 (2.35 to 3.68)	18.0 (16.8 to 19.2)	–27.7 (–49.0 to –1.96)	–38.9 (–45.2 to –31.8)
Zambia	5.82 (4.75 to 6.99)	26.3 (24.9 to 27.7)	–10.0 (–32.5 to 18.6)	4.43 (–5.87 to 16.0)
Southern sub-Saharan Africa	8.70 (7.51 to 10.0)	34.6 (33.3 to 35.7)	–36.8 (–47.8 to –25.7)	–22.7 (–26.0 to –18.9)
Botswana	8.39 (7.02 to 9.77)	36.3 (34.4 to 38.2)	–19.1 (–38.0 to 7.26)	–6.48 (–14.6 to 1.90)
eSwatini	2.87 (2.28 to 3.67)	15.0 (13.6 to 16.5)	–26.9 (–47.4 to –0.171)	–30.9 (–38.9 to –21.5)
Lesotho	1.85 (1.42 to 2.42)	41.5 (39.6 to 43.5)	4.41 (–27.9 to 50.9)	29.5 (17.1 to 42.3)
Namibia	10.6 (8.83 to 12.7)	23.5 (21.9 to 25.1)	–25.7 (–43.6 to –5.01)	–21.6 (–29.4 to –13.3)
South Africa	10.4 (8.75 to 12.2)	35.4 (33.8 to 36.9)	–38.0 (–50.2 to –24.8)	–27.5 (–31.3 to –23.3)
Zimbabwe	3.47 (2.73 to 4.29)	34.4 (32.6 to 36.0)	–8.90 (–35.9 to 24.1)	3.59 (–5.33 to 13.2)
Western sub-Saharan Africa	1.81 (1.64 to 2.02)	12.7 (12.2 to 13.1)	–33.7 (–42.9 to –23.7)	–23.0 (–26.9 to –18.9)
Benin	1.69 (1.28 to 2.15)	10.6 (9.77 to 11.5)	–45.1 (–63.0 to –23.6)	–42.3 (–49.6 to –34.4)
Burkina Faso	1.47 (1.10 to 1.93)	17.0 (15.7 to 18.4)	–32.4 (–55.1 to –1.13)	–28.2 (–36.7 to –18.4)
Cameroon	1.51 (1.14 to 1.94)	14.8 (13.5 to 16.2)	–24.1 (–47.2 to 6.20)	–33.9 (–42.5 to –24.7)
Cape Verde	3.00 (2.36 to 3.83)	9.39 (8.41 to 10.5)	–35.2 (–54.4 to –9.63)	–45.5 (–53.3 to –36.9)
Chad	2.83 (2.23 to 3.63)	16.0 (14.7 to 17.4)	–33.7 (–54.0 to –7.61)	–30.4 (–38.9 to –20.5)
Côte d'Ivoire	3.79 (2.89 to 4.83)	21.8 (20.0 to 23.7)	0.960 (–28.8 to 37.6)	10.9 (–3.13 to 26.9)
The Gambia	1.33 (1.02 to 1.72)	23.6 (21.9 to 25.3)	–35.0 (–55.2 to –9.14)	–32.4 (–39.2 to –25.1)
Ghana	2.08 (1.58 to 2.72)	10.5 (9.42 to 11.6)	6.37 (–26.7 to 56.4)	–7.41 (–20.7 to 7.27)
Guinea	2.03 (1.54 to 2.56)	29.2 (26.6 to 31.9)	–5.65 (–34.9 to 30.1)	–8.87 (–19.3 to 2.07)
Guinea-Bissau	1.07 (0.811 to 1.39)	8.46 (7.42 to 9.54)	3.39 (–29.1 to 46.7)	16.3 (–2.20 to 38.5)
Liberia	2.57 (2.03 to 3.24)	13.7 (12.5 to 15.0)	1.62 (–30.8 to 43.3)	–12.8 (–24.2 to 0.646)
Mali	2.44 (1.83 to 3.22)	22.5 (20.8 to 24.1)	47.6 (–2.39 to 113)	27.0 (12.4 to 44.0)
Mauritania	8.08 (6.28 to 10.1)	29.3 (26.8 to 31.8)	–12.3 (–39.3 to 20.6)	–21.6 (–29.5 to –11.8)
Niger	1.63 (1.23 to 2.16)	14.1 (12.8 to 15.6)	18.3 (–21.9 to 68.9)	12.0 (–5.17 to 30.8)

(Table continues on next page)

	Age-standardised prevalence, 2019		Percentage change 1990–2019	
	Females	Males	Females	Males
(Continued from previous page)				
Nigeria	1.16 (0.862 to 1.54)	7.43 (6.69 to 8.21)	–53.3 (–67.9 to –33.2)	–38.5 (–46.7 to –30.1)
São Tomé and Príncipe	1.70 (1.29 to 2.22)	7.80 (6.95 to 8.69)	15.1 (–23.8 to 70.5)	24.2 (5.43 to 43.3)
Senegal	1.46 (1.11 to 1.90)	14.2 (13.2 to 15.3)	–41.2 (–60.4 to –17.5)	–52.3 (–57.5 to –46.0)
Sierra Leone	7.84 (6.34 to 9.61)	30.5 (28.7 to 32.6)	–26.1 (–46.8 to 0.307)	–13.1 (–21.4 to –3.07)
Togo	2.26 (1.73 to 2.92)	14.0 (12.8 to 15.2)	–37.3 (–57.5 to –11.9)	–42.8 (–49.8 to –35.5)

Data are given to three significant figures. Data in parentheses are 95% uncertainty intervals.

**Table: Age-standardised prevalence of current smoking tobacco use in 2019 and percentage change in age-standardised prevalence of current smoking tobacco use in 1990–2019 among individuals aged 15 years and older, by location and sex**




**Figure 1: Annualised rate of change in number of tobacco smokers (A) and age-standardised prevalence of smoking tobacco use (B), by super-region**  
Bold lines show regional averages, and thin lines show country-level changes.

increased significantly over the past 30 years in 20 countries for males (Afghanistan, Saudi Arabia, Uzbekistan, El Salvador, Antigua and Barbuda, Lesotho, Congo [Brazzaville], Mali, Albania, Lebanon, São Tomé and Príncipe, Bosnia and Herzegovina, Gabon, Djibouti, Egypt, Jordan, Mongolia, Laos, Kiribati, and Indonesia) and in 12 countries for females (Afghanistan, Albania, Kyrgyzstan, Saudi Arabia, Lebanon, Mongolia, Bosnia and Herzegovina, Belarus, Portugal, Lithuania, Russia, and Serbia; table). Across both sexes combined, the largest decreases in age-standardised prevalence of smoking tobacco use were observed in Brazil (73.4% [71.4–75.2]), Norway (53.5% [49.1–57.6]), Senegal (50.9% [44.6–56.0]), Iceland (49.7% [44.5–54.1]), Denmark (49.3% [46.4–52.2]), Haiti (47.5% [40.5–54.4]),

Australia (47.5% [43.1–51.8]), Costa Rica (47.4% [40.5–53.6]), Canada (47.4% [42.4–52.0]), and Colombia (47.1% [40.4–53.4]; appendix 2 pp 94–102).

Analysing the annualised rate of change per 5-year period in individuals aged 15 years and older between 1990 and 2019, we found the largest number of countries had their fastest decrease in age-standardised prevalence of smoking tobacco use between 2005 and 2009 for both males (68 countries) and females (56 countries; figure 1; country-level data are available online through the GHDx). Overall, 115 (56%) of 204 countries for males and 136 (67%) countries for females had their fastest decrease after the FCTC was ratified (ie, after 2005). Notably, decreases in prevalence were smaller in the period 2015–19 than in the period 2010–15 in

For country-level data see  
<http://ghdx.healthdata.org/record/ihme-data/gbd-2019-smoking-tobacco-use-prevalence-1990-2019>



**Figure 2:** Distribution of number of tobacco smokers aged 30 years and older, by cigarette-equivalents smoked per day (A), and pack-years among current smokers (B), and years since quitting among former smokers (C), by sex and geographical region in 2019

Cigarette-equivalents smoked per day and pack-years are two different indicators of exposure among the current smoker population.

152 (75%) countries for males and 137 (67%) countries for females (figure 1; country-level data are available online through the GHDx).

In many countries, reductions in prevalence have not kept pace with population growth (figure 1; appendix 2 pp 94–102). As a result, the number of smokers globally has increased steadily each year since 1990, when there were 0·99 billion (95% UI 0·98–1·00) smokers globally, with the exception of the period between 2011 and 2017, during which no significant change in the number of smokers occurred (figure 1). Of 204 countries and territories included in our analysis, 113 (55%) had a significant increase in the number of current smokers between 1990 and 2019 and 111 (54%) had a significant increase between 2005 and 2019. Among both males and females, the super-regions with the largest relative increases in the number of smokers since 1990 were north Africa and the Middle East (104·1% [98·1–111] increase) and sub-Saharan Africa (74·6% [69·9–79·1] increase; appendix 2 pp 94–102). The largest relative decreases in the number of smokers were observed in the Latin America and the Caribbean (19·8% [16·9–22·5] decrease) and high-income (17·6% [16·2–18·9] decrease) super-regions.

7·41 trillion (95% UI 7·11–7·74) cigarette-equivalents of tobacco were consumed in 2019, amounting to 20·3 billion (19·5–21·2) cigarette-equivalents consumed each day worldwide. China accounted for more than a third of the world's tobacco consumption (2·72 trillion [2·47–3·01] cigarette-equivalents). Countries with the highest consumption per person in 2019 were mostly in Europe, with Montenegro, North Macedonia, Bulgaria, Slovenia, and

Greece all having consumption exceeding 2350 cigarette-equivalents per person (appendix 2 pp 103–111). Countries with the lowest consumption per person were mostly in sub-Saharan Africa (appendix 2 pp 103–110).

Cigarettes smoked per day is an important predictor of disease risk, although smokers who consume only a few cigarettes each day still have considerable excess risk compared with non-smokers. Among 719 million male current smokers aged 30 years and older in 2019, 83·2 million (11·6%) smoked 1–4 cigarette-equivalents per day, 139·2 million (19·4%) smoked 5–9 cigarette-equivalents per day, 144·0 million (20·0%) smoked 10–14 cigarette-equivalents per day, 120·5 million (16·8%) smoked 15–19 cigarette-equivalents per day, and 231·9 million (32·3%) smoked 20 or more cigarette-equivalents per day (figure 2). Among 146 million female current smokers aged 30 years and older in 2019, 27·0 million (18·5%) smoked 1–4 cigarette-equivalents per day, 39·0 million (26·7%) smoke 5–9 cigarette-equivalents per day, 32·4 million (22·1%) smoked 10–14 cigarette-equivalents per day, 20·8 million (14·2%) smoked 15–19 cigarette-equivalents per day, and 27·1 million (18·5%) smoked 20 or more cigarette-equivalents per day (figure 2). The distribution of cigarette-equivalents per smoker per day varies across countries. Most of the male current smoker population aged 30 years and older in 72 countries and most of the female current smoker population in 121 countries smoke fewer than 10 cigarette-equivalents per day on average (data not shown).

In 2019, 7·69 million (95% UI 7·16–8·20) deaths and 200 million (185–214) DALYs were attributable to

smoking tobacco use, accounting for 13·6% (13·0–14·3) of all deaths and 7·89% (7·19–8·56) of all DALYs (appendix 2 pp 112–165). 6·18 million (80%) of these deaths were among males, and smoking accounted for the largest number and proportion (20·2% [19·3–21·1]) of deaths among males of the 87 risk factors included in GBD 2019.<sup>1</sup> Among females, smoking accounted for 1·51 million (1·40–1·63) deaths and 5·84% (5·47–6·22) of all deaths. YLLs due to smoking tobacco use, which quantify the effects of premature mortality, exceeded YLDs due to smoking in 2019, which quantify the effects of non-fatal health loss, (168 million [156–180] YLLs vs 31·6 million [23·7–40·0] YLDs). The ratio of YLLs to YLDs attributable to smoking tobacco use varied across countries, from 1·59 (1·03–2·44) in Qatar to 16·1 (11·2–22·7) in the Solomon Islands (appendix 2 pp 166–174). Ratios of YLLs to YLDs decreased with increasing Socio-demographic Index level (appendix 2 p 175). Lower ratios of YLLs to YLDs indicate that a greater proportion of individuals are living with chronic health conditions due to smoking tobacco use in these countries than in countries with higher ratios of YLLs to YLDs.

Of the 36 health outcomes caused by smoking tobacco use (appendix 2 pp 5–82), the health outcomes with the largest number of deaths attributable to smoking tobacco use for both sexes combined in 2019 were ischaemic heart disease (1·68 million [95% UI 1·56–1·81]); chronic obstructive pulmonary disease (1·59 million [1·41–1·76]); tracheal, bronchus, and lung cancer (1·31 million [1·20–1·43]); and stroke (0·931 million [0·833–1·00]; appendix 2 pp 176–177), which together accounted for approximately 72% of all deaths attributable to smoking tobacco use that year. Top causes of death attributable to smoking varied by region, reflecting differences in both background cause-specific death rates and patterns of smoking. Ischaemic heart disease was the leading cause of deaths attributable to smoking tobacco use in all super-regions except the high-income super-region, for which the leading cause was lung cancer, and for countries in the southeast Asia, east Asia, and Oceania super-region for which the leading cause was chronic obstructive pulmonary disease (appendix 2 pp 176–177).

An estimated 5·96 million (77·5%) of 7·69 million deaths attributable to smoking tobacco use occurred in low-income and middle-income countries in 2019. Ukraine had the highest death rate from smoking among males (487 per 100 000 males [95% UI 396–590; appendix 2 pp 112–138). Countries with high rates of deaths attributable to smoking tobacco use among males were predominantly in the central Europe, eastern Europe, and east Asia regions. Among females, four locations had rates of deaths attributable to smoking tobacco use higher than 180 per 100 000 females (Denmark, Montenegro, Serbia, and Greenland; appendix 2 pp 112–138).

Across all age groups, smoking tobacco use was the cause of more than 20% of all male deaths in 73 countries in 2019 (figure 3). 43 (59%) of 73 countries were

designated as low-income or middle-income countries. Among all females, smoking accounted for more than 20% of deaths in only two locations (Denmark and Greenland), due to both lower smoking prevalence, shorter duration of smoking, and lower smoking intensity among females than among males (figure 3). The proportion of deaths attributable to smoking tobacco use increased with age, peaking among those aged 60–64 years (22·0% [95% UI 21·1–23·1] of deaths attributable to smoking), before decreasing in older age groups (appendix 2 p 178).

The share of all-cause deaths that were due to smoking tobacco use decreased significantly between 1990 and 2019 in 68 countries, increased significantly in 71 countries, and stayed constant in 65 countries (appendix 2 pp 179–187). 66 (93%) of 71 countries with significant increases in the proportion of all-cause deaths attributable to smoking tobacco use were low-income and middle-income countries. The largest decreases were observed in Australia, New Zealand, South Africa, Singapore, and Norway, whereas the largest increases were observed in Timor-Leste, Bhutan, Niger, São Tomé and Príncipe, and Malawi (appendix 2 pp 179–187). The largest absolute increases in the number of deaths attributable to tobacco smoking between 1990 and 2019 were observed in China (from 1·5 million deaths in 1990 to 2·4 million in 2019; a 57·9% [26·2–101] increase), India (from 0·6 million deaths in 1990 to 1·0 million in 2019; a 58·9% [30·7–90·8] increase), and Indonesia (from 112 800 deaths in 1990 to 246 400 deaths in 2019; a 118% [74·0–171] increase; appendix 2 pp 179–187).

The dose-response association between risk exposure and disease results in an uneven distribution of burden among the current and former smoking populations aged 30 years and older (figure 4). Among ever smokers aged 30 years and older, 865 million (65·9%) of 1·31 billion are current smokers and 449 million (34·1%) are former smokers. A disproportionate share of all deaths attributable to smoking tobacco use occurred among current smokers (6·68 million [86·9%] of 7·69 million). Among former smokers, health risks decreased as a function of years since cessation (figure 4). Only 0·467 million (6·18%) global deaths attributable to smoking tobacco use occurred among individuals who had quit smoking at least 15 years ago, despite this group accounting for 257 million (19·6%) members of the global ever smoker population.

## Discussion

In this study, we present updated results on the prevalence of smoking tobacco use and the attributable disease burden from GBD 2019. We used new direct estimation methods, which allowed more comprehensive estimations, including reflecting dose-response associations between exposure and risk of disease and capture of health effects among daily and occasional smokers and former smokers. By using continuous





Figure 3: Proportion of all-cause deaths that were attributable to smoking tobacco use among females (A) and males (B) of all ages in 2019





**Figure 4:** Number of deaths from cancers and chronic obstructive pulmonary disease (A) and deaths from cardiovascular and circulatory diseases and all other health outcomes (excluding cancers and chronic obstructive pulmonary disease; B) attributable to smoking tobacco use in individuals aged 30 years and older, by level of exposure, sex, and super-region

exposure measures, we are better able to capture differences in risk across countries that result from heterogeneous smoking patterns. Our findings are an urgent call to action for countries to implement and enforce stronger tobacco control policies than are currently in place, and serve as a blueprint for targeting interventions, monitoring progress, allocating resources, and planning for future health system strain.

In 2019, more than 1 billion people smoked tobacco regularly, and almost 8 million deaths were attributable

to smoking. Smoking tobacco use accounted for 20·2% of all-cause deaths among males, and was the leading risk factor for both deaths and DALYs among males. Among females, smoking tobacco use accounted for approximately 5·8% of all deaths, due to lower prevalence, shorter duration, and lower intensity of smoking than in males. Tobacco control has contributed to reductions in global prevalence of smoking tobacco use of 27·5% (95% UI 26·5–28·5) for males and 37·7% (35·4–39·9) for females. However, these global aggregates do not illustrate important between-country heterogeneity. Between 1990 and 2019, significant decreases in prevalence of smoking tobacco use were observed in 135 countries for males and 68 countries for females, while significant increases were observed in 20 countries for males and 12 countries for females.

Although tobacco control efforts began as early as in the 1960s in some countries after the detrimental health effects of tobacco smoking were first documented, global progress in tobacco control was catalysed with the passing of the WHO FCTC in 2005.<sup>9,33</sup> The decade following the introduction of the WHO FCTC was the period of fastest decrease in the prevalence of smoking tobacco use across the largest number of countries.<sup>34</sup> The effectiveness of the demand-reduction policies outlined in the FCTC articles has been documented, and the large reductions in prevalence of smoking tobacco use between 1990 and 2019 were observed in Brazil (73·4% decrease), Norway (53·5% decrease), and Senegal (50·9% decrease), along with Iceland, Denmark, Canada, Australia, Colombia, and Costa Rica, all with decreases in prevalence exceeding 45%, show the potential of these tools to operate in diverse contexts to greatly reduce the prevalence of smoking tobacco use and save millions of lives over the coming decades.<sup>35–38</sup>

Despite these successes, we observed three concerning patterns. First, in several countries with large populations and high prevalence of smoking tobacco use, including China (2·4 million deaths in 2019, a 57·9% [95% UI 26·2–101] increase in attributable deaths since 1990) and Indonesia (246 400 deaths in 2019, a 118% [74·0–171] increase in attributable deaths since 1990), little to no progress has been made in reducing the prevalence of smoking. Second, most countries did not have sufficient decreases in the prevalence of smoking to offset the demographic force of population growth, resulting in constant or increasing numbers of smokers over time. And third, in many countries, including those that had large decreases in prevalence previously, the rate of progress has slowed, particularly in the past 5 years.

113 of 204 countries had a significant increase in the number of smokers since 1990, and 111 countries had a significant increase since 2005. To achieve the goals set forth in the SDGs and WHO global non-communicable disease monitoring framework, and in doing so reclaim the 200 million DALYs lost to smoking tobacco use each year, most countries will need



stronger tobacco control policies than those already in place. As of 2018, only 62 countries had comprehensive smoke-free policies; 23 offered the full range of cessation support services recommended by WHO; 91 mandated best-practice pictorial health warnings; 48 were protected by complete advertising, promotion, and sponsorship bans; and 38 had the recommended level of tobacco taxation.<sup>10</sup> Closing gaps in the adoption, implementation, and enforcement of evidence-based demand-reduction policies is vital to ending the global tobacco epidemic.

Taxation is one of the most effective tobacco control policies available to countries.<sup>4</sup> Increasing taxes decreases demand by reducing the affordability of tobacco products. As income and purchasing power increase, particularly in rapidly developing countries, concordant increases in tobacco taxes to reduce affordability are necessary for this fiscal policy to remain potent. Yet, between 2008 and 2018, the affordability of cigarettes decreased in only 33% of low-income countries compared with in 38% of middle-income countries and 72% of high-income countries.<sup>10</sup> Only one low-income country, Madagascar, taxes tobacco at the rate recommended by the WHO MPOWER framework. Low-income and middle-income countries face the additional challenge of population growth expanding their smoking population. Tobacco taxation is a highly cost-effective measure, and when combined with a progressive approach to redistributing revenue from taxation to tobacco control programmes, health care, and other social support services, can greatly reduce the prevalence of smoking and substantially improve population health.<sup>39</sup>

With 1.14 billion current smokers globally in 2019, increasing cessation rates among current smokers can yield massive health gains. We estimated that fewer than 15% of deaths attributable to smoking tobacco use in 2019 occurred among former smokers aged 30 years and older, despite former smokers comprising approximately a third of the ever smoker population aged 30 years and older. Consistent with other studies, we found in our meta-analyses of risk reduction among former smokers that cessation shifts smokers into a lower-risk category, with greater reduction in risk for longer durations since cessation.<sup>40–42</sup> Relative risks of all-cause mortality from long-running cohort studies in the UK<sup>41,42</sup> and the USA<sup>43</sup> indicate that up to two-thirds of long-term smokers will eventually die of a disease attributable to smoking. These data underscore the importance of adopting policies and interventions that increase rates of cessation.

The results of our study must be interpreted in the context of several limitations. First, data on smoking tobacco use are self-reported, which might lead to underestimates in demographic groups with low social acceptability of smoking, particularly among females in Asia and Africa.<sup>44</sup> Second, the scope of our study focuses on smoked tobacco products, and does not include smokeless tobacco products, e-cigarettes, heated tobacco

products, or other electronic nicotine delivery systems. Incorporating the health effects of the array of emerging electronic nicotine delivery systems, including both potential benefits and potential harms, is becoming increasingly important. Additionally, our analysis focuses on the health effects of primary smoking of tobacco and does not include additional harms due to second-hand smoke. Third, we converted non-cigarette smoked tobacco products to cigarette-equivalents on the basis of the weight of tobacco. Conversion on the basis of health effect equivalencies would be more accurate, but a paucity of evidence on the health effects of non-cigarette tobacco products presents challenges to this alternative approach. Fourth, the optimal lag-time between exposure and outcome exceeded 10 years for five outcomes (ischaemic heart disease, lower respiratory tract infections, aortic aneurysm, peripheral artery disease, and peptic ulcer disease). Due to the paucity of data on smoking patterns before 1980, we were restricted to using a maximum lag-time of 10 years. Fifth, the rate of risk reduction among former smokers probably varies by smoking intensity. Although we captured differences in the level of risk, we did not capture differences in the rate of risk reduction in our estimates. Despite these limitations, our results are broadly consistent with previous estimates that use different methods with a different set of limitations.<sup>20</sup>

Smoking remains a defining challenge in global health. Governments, and particularly ministers of health, face substantial obstacles ranging from population growth, to pressure from the tobacco industry, to competing health and political priorities. Nevertheless, it is increasingly important for all countries to adopt, implement, and enforce comprehensive packages of evidence-based tobacco control policies. The current level of tobacco control policy implementation is insufficient in many countries around the world. With more than 1 billion people smoking tobacco globally as of 2019, the annual death toll, economic costs, and burden to health systems caused by smoking will increase in the years to come unless countries take swift and strong action to substantially reduce their smoking rates.

#### Contributors

Please see appendix 1 (pp 67–72) for more detailed information about individual author contributions to the research, divided into the following categories: managing the estimation or publication process; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures and tables; providing data or critical feedback on data sources; development of methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; extracting, cleaning, or cataloguing data; designing or coding figures and tables; and managing the overall research enterprise.

#### GBD 2019 Tobacco Collaborators

Marissa B Reitsma, Parkes J Kendrick, Emad Ababneh, Cristiana Abbafati, Mohsen Abbasi-Kangevari, Amir Abdoli, Aidin Abedi,

E S Abhilash, Derrick Bary Abila, Victor Aboyans, Niveen ME Abu-Rmeileh, Oladimeji M Adebayo, Shailesh M Advani, Mohammad Aghaali, Bright Opoku Ahinkorah, Sohail Ahmad, Keivan Ahmadi, Haroon Ahmed, Budi Aji, Chisom Joyqueenet Akunna, Ziyad Al-Aly, Turki M Alanzi, Khalid F Alhabib, Liaqat Ali, Sheikh Mohammad Alif, Vahid Alipour, Syed Mohamed Aljunid, François Alla, Peter Allebeck, Nelson Alvis-Guzman, Tarek Tawfik Amin, Saeed Amini, Hubert Amu, Gianna Gayle Herrera Amul, Robert Ancuceanu, Jason A Anderson, Alireza Ansari-Moghaddam, Carl Abelardo T Antonio, Benny Antony, Davood Anvari, Jalal Arabloo, Nicholas D Arian, Monika Arora, Malke Asaad, Marcel Ausloos, Asma Tahir Awan, Getinet Ayano, Getie Lake Aynalem, Samad Azari, Darshan B B, Ashish D Badiye, Atif Amin Baig, Mohammad Hossein Bakhshaei, Maciej Banach, Palash Chandra Banik, Suzanne Lyn Barker-Collo, Till Winfried Bärnighausen, Hiba Jawdat Barqawi, Sanjay Basu, Mohsen Bayati, Shahrzad Bazargan-Hejazi, Masoud Behzadifar, Tariku Tesfaye Bekuma, Derrick A Bennett, Isabela M Bensenor, Kathleen S Sachiko Berfield, Akshaya Srikanth Bhagavathula, Nikha Bhardwaj, Pankaj Bhardwaj, Kritika Bhattacharyya, Sadia Bibi, Ali Bijani, Bagas Suryo Bintoro, Antonio Biondi, Setognal Birara, Dejana Braithwaite, Hermann Brenner, Andre R Brunoni, Katrin Burkart, Zahid A Butt, Florentino Luciano Caetano dos Santos, Luis Alberto Cámera, Josip Car, Rosario Cárdenas, Giulia Carreras, Juan J Carrero, Joao Mauricio Castaldelli-Maia, Maria Sofia Sofia Cattaruzza, Jung-Chen Chang, Simiao Chen, Dinh-Toi Chu, Sheng-Chia Chung, Massimo Cirillo, Vera Marisa Costa, Rosa A S Couto, Omid Dadras, Xiaochen Dai, Albertino Antonio Moura Damasceno, Giovanni Damiani, Lalit Dandona, Rakhi Dandona, Parnaz Daneshpajouhnejad, Jiregna Darega Gela, Kairat Davletov, Meseret Derbew Molla, Getenet Ayalew Dessie, Abebaw Alemayehu Desta, Samath Dhamminda Dharmaratne, Mostafa Dianatinasab, Daniel Diaz, Hoa Thi Do, Abdel Douiri, Bruce B Duncan, Andre Rodrigues Duraes, Arielle Wilder Eagan, Mohammad Ebrahimi Kalan, Kristina Edvardsson, Iffat Elbarazi, Maha El Tantawi, Saman Esmaeilnejad, Ibtihal Fadhil, Emerito Jose A Faraon, Carla Sofia e Sá Farinha, Medhat Farwati, Farshad Farzadfar, Mehdi Fazlzadeh, Valery L Feigin, Rachel Feldman, Carlota Fernandez Prendes, Pietro Ferrara, Irina Filip, Filippas Filippidis, Florian Fischer, Luisa Sorio Flor, Nataliya A Foigt, Morenike Oluwatoyin Folayan, Masoud Foroutan, Mohamed M Gad, Abhay Motiramji Gaidhane, Silvano Gallus, Biniyam Sahiledengle Geberemariam, Mansour Ghafourifard, Alireza Ghajar, Ahmad Ghashghae, Simona Giampaoli, Paramjit Singh Gill, Franklin N Glozah, Elena V Gnedovskaya, Mahaveer Golechha, Sameer Vali Gopalani, Giuseppe Gorini, Houman Goudarzi, Alessandra C Goulart, Felix Greaves, Avirup Guha, Yuming Guo, Bhawna Gupta, Rajat Das Gupta, Rajeev Gupta, Tarun Gupta, Vin Gupta, Nima Hafezi-Nejad, Mohammad Rifat Haider, Randah R Hamadeh, Graeme J Hankey, Arief Hargono, Risky Kusuma Hartono, Hadi Hassankhani, Simon I Hay, Golnaz Heidari, Claudiu Herteliu, Kamal Hezam, Thomas R Hird, Michael K Hole, Ramesh Holla, Mehdi Hosseinzadeh, Sorin Hostiuc, Mowafa Househ, Thomas Hsiao, Junjie Huang, Vincent C Iannucci, Segun Emmanuel Ibitoye, Bulat Idrisov, Olayinka Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, Leeberk Raja Inbaraj, Seyed Sina Naghibi Irvani, Jessica Y Islam, Rakibul M Islam, Sheikh Mohammed Shariful Islam, Farhad Islami, Hiroyasu Iso, Ramaiah Itumalla, Masao Iwagami, Jalil Jaafari, Vardhmaan Jain, Mihajlo Jakovljevic, Sung-In Jang, Hosna Janjani, Shubha Jayaram, Panniyammakal Jeemon, Ravi Prakash Jha, Jost B Jonas, Tamas Joo, Mikl Jürisson, Ali Kabir, Zubair Kabir, Leila R Kalankesh, Tanuj Kanchan, Himal Kandel, Neeti Kapoor, Salah Eddin Karimi, Srinivasa Vittal Katikireddi, Hafte Kahsay Kebede, Bayew Kelkay, Ryan David Kennedy, Abdullah T Khoja, Jagdish Khubchandani, Gyu Ri Kim, Young-Eun Kim, Ruth W Kimokoti, Mika Kivimäki, Soewarta Kosen, Sindhura Lakshmi Koulmane Laxminarayana, Ai Koyanagi, Kewal Krishan, Nuworza Kugbey, G Anil Kumar, Nithin Kumar, Om P Kurmi, Dian Kusuma, Ben Lacey, Jennifer O Lam, Iván Landires, Savita Lasrado, Paolo Lauriola, Doo Woong Lee, Yo Han Lee, Janni Leung, Shanshan Li, Hualiang Lin, Shai Linn, Wei Liu, Alan D Lopez, Platon D Lopukhov, Stefan Lorkowski, Alessandra Lugo, Azeem Majeed, Afshin Maleki, Reza Malekzadeh, Deborah Carvalho Malta, Abdullah A Mamun, Narayana Manjunatha, Borhan Mansouri, Mohammad Ali Mansournia, Jose Martinez-Raga, Santi Martini, Manu Raj Mathur, Carlo Eduardo Medina-Solis, Suresh Mehata, Walter Mendoza, Ritesh G Menezes, Atte Meretoja, Tuomo J Meretoja, Bartosz Miazgowski, Irmira Maria Michalek, Ted R Miller, Erkin M Mirrakhimov, Hamed Mirzaei, Mehdi Mirzaei-Alavijeh, Sanjeev Misra, Masoud Moghadaszadeh, Yousef Mohammad, Abdollah Mohammadian-Hafshejani, Shafiu Mohammed, Ali H Mokdad, Lorenzo Monasta, Mohammad Ali Moni, Ghobad Moradi, Maziar Moradi-Lakeh, Rahmatollah Moradzadeh, Shane Douglas Morrison, Tilahun Belete Mossie, Sumaira Mubarak, Erin C Mullany, Christopher J L Murray, Mohsen Naghavi, Behshad Naghshtabrizi, Sanjeev Nair, Mahdi Nalini, Vinay Nangia, Atta Abbas Naqvi, Sreenivas Narasimha Swamy, Muhammad Naveed, Smitha Nayak, Vinod C Nayak, Javad Nazari, Sabina O Nduaguba, Sandhya Neupane Kandel, Cuong Tat Nguyen, Huong Lan Thi Nguyen, Son Hoang Nguyen, Trang Huyen Nguyen, Molly R Nixon, Chukwudi A Nnaji, Bo Norrving, Jean Jacques Noubiap, Christoph Nowak, Felix Akpoje Ogb, Ayodipupo Sikiru Oguntade, In-Hwan Oh, Andrew T Olagunju, Eyal Oren, Nikita Ostavnov, Stanislav S Ostavnov, Mayowa O Owolabi, Mahesh P A, Smita Pakhale, Keyvan Pakshir, Raffaele Palladino, Adrian Pana, Songhomitra Panda-Jonas, Ashok Pandey, Utsav Parekh, Eun-Cheol Park, Eun-Ke Park, Fatemeh Pashazadeh Kan, George C Patton, Shrikant Pawar, Richard G Pestell, Marina Pinheiro, Michael A Piradov, Saeed Pirouzpanah, Khem Narayan Pokhrel, Roman V Polibin, Akila Prashant, Dimas Ria Angga Pribadi, Amir Radfar, Vafa Rahimi-Movaghgar, Azizur Rahman, Mohammad Hifz Ur Rahman, Muhammad Aziz Rahman, Amir Masoud Rahmani, Nazanin Rajai, Pradhum Ram, Chhabhi Lal Ranabhat, Priya Rath, Lal Rawal, Andre M N Renzaho, Luz Myriam Reynales-Shigematsu, Aziz Rezapour, Seyed Mohammad Riahi, Mavra A Riaz, Leonardo Roeber, Luca Ronfani, Gholamreza Roshandel, Ambuj Roy, Bedanta Roy, Simona Sacco, Basema Saddik, Amirhossein Sahebkar, Sana Salehi, Hamideh Salimzadeh, Mehrmoosh Samaei, Abdallah M Samy, Itamar S Santos, Milena M Santric-Milicevic, Nizal Sarrafzadegan, Brijesh Sathian, Monika Sawhney, Mete Saylan, Michael P Schaub, Maria Inês Schmidt, Ione Jayce Ceola Schneider, Aletta Elisabeth Schutte, Falk Schwendicke, Abdul-Aziz Seidu, Nachimuthu Senthil Kumar, Sadaf G Sepanlou, Allen Seylani, Omid Shafaat, Syed Mahboob Shah, Masoud Ali Shaikh, Ali S Shalash, Mohammed Shannawaz, Kiomars Sharafi, Aziz Sheikh, Sara Sheikhbahaei, Mika Shigematsu, Rahman Shiri, Kawkab Shishani, K M Shivakumar, Siddharudha Shivalli, Roman Shrestha, Soraya Siabani, Negussie Boti Sidemo, Inga Dora Sigfusdottir, Rannveig Sigurvinsdottir, Diego Augusto Santos Silva, João Pedro Silva, Ambrish Singh, Jasvinder A Singh, Virendra Singh, Dharendra Narain Sinha, Freddy Sitas, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, Matiws Soboka, Joan B Soriano, Ali Soroush, Sergey Soshnikov, Ireneous N Soyiri, Emma Elizabeth Spurlock, Chandrashekhar T Sreeramreddy, Dan J Stein, Paschalis Steiropoulos, Stefan Stortecyk, Kurt Straif, Rizwan Suliankatchi Abdulkader, Gerhard Sulo, Johan Sundström, Takahiro Tabuchi, Santosh Kumar Takamakadla, Biruk Wogayehu Taddele, Eyayou Girma Tadesse, Anmut Tagele Tamiru, Minale Tareke, Md Ismail Tareque, Ingan Ukur Tarigan, Mohamad-Hani Temsah, Kavumpurathu Raman Thankappan, Rekha Thapar, Ales Tichopad, Musliu Adetola Tolani, Fotis Topouzis, Marcos Roberto Tovani-Palone, Bach Xuan Tran, Jaya Prasad Tripathy, Gebiyaw Wudie Tsegaye, Nikolaos Tsilimparis, Hayley D Tymeson, Anayat Ullah, Saif Ullah, Brigid Unim, Rachel L Updike, Marco Vacante, Pascual R Valdez, Constantine Vardavas, Patricia Varona Pérez, Tommi Juhani Vasankari, Narayanaswamy Venketasubramanian, Madhur Verma, Marina V Vetrova, Bay Vo, Giang Thu Vu, Yasir Waheed, Yanzhong Wang, Kevin Welding, Andrea Werdecker, Joanna L Whisnant, Nuwan Darshana Wickramasinghe, Kazumasa Yamagishi, Srikanth Yandrapalli, Hiroshi Yatsuya, Vahid Yazdi-Feyzabadi,

Yigizie Yeshaw, Mohammed Zewdu Yimmer, Naohiro Yonemoto, Chuanhua Yu, Ismaeel Yunusa, Hasan Yusefzadeh, Telma Zahirian Moghadam, Muhammed Shahriar Zaman, Maryam Zamanian, Hamed Zandian, Heather J Zar, Mikhail Sergeevich Zastrozhin, Anastasia Zastrozhina, Luis Zavala-Arciniega, Jianrong Zhang, Zhi-Jiang Zhang, Chenwen Zhong, Yves Miel H Zuniga, Emmanuela Gakidou.

# Affiliations

Institute for Health Metrics and Evaluation (M B Reitsma BS, P J Kendrick BS, J A Anderson BS, N D Arian BA, K Burkart PhD, X Dai PhD, Prof L Dandona MD, Prof R Dandona PhD, Prof S D Dharmaratne MD, Prof V L Feigin PhD, R Feldman BS, V Gupta MD, Prof S I Hay FMedSci, T Hsiao BS, V C Iannucci BA, Prof A D Lopez PhD, Prof A H Mokdad PhD, E C Mullany BA, Prof C J L Murray PhD, Prof M Naghavi MD, M R Nixon PhD, E E Spurlock BA, H D Tymeson BA, R L Updike MPH, J L Whisnant MPH, Prof E Gakidou PhD), Department of Surgery (K S S Berfield MD), Department of Health Metrics Sciences, School of Medicine (K Burkart PhD, Prof R Dandona PhD, Prof S D Dharmaratne MD, V Gupta MD, Prof S I Hay FMedSci, Prof A D Lopez PhD, Prof A H Mokdad PhD, Prof C J L Murray PhD, Prof M Naghavi MD, Prof E Gakidou PhD), University of Washington, Seattle, WA, USA (Prof E Oren PhD); Pathology and Laboratory Medicine Institute (E Ababneh MD), Internal Medicine Department (M Farwati MD), Department of Cardiovascular Medicine (M M Gad MD), Department of Internal Medicine (V Jain MD), Cleveland Clinic, Cleveland, OH, USA; Department of Juridical and Economic Studies (C Abbafati PhD), Department of Public Health and Infectious Diseases (M S Cattaruzza PhD), La Sapienza University, Rome, Italy; Social Determinants of Health Research Center (M Abbasi-Kangevari MD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Parasitology and Mycology (A Abdoli PhD), Jahrom University of Medical Sciences, Jahrom, Iran; Department of Orthopaedic Surgery (A Abedi MD), Department of Radiology (S Salehi MD), University of Southern California, Los Angeles, CA, USA; Department of Botany (E S Abhilash PhD), Sree Narayana Guru College Chelannur, Kozhikode, India; Department of Pathology (D B Abila BSc), Makerere University, Kampala, Uganda; Faculty of Biology, Medicine, and Health (D B Abila BSc), University of Manchester, Manchester, UK; Department of Cardiology (Prof V Aboyans MD), Dupuytren University Hospital, Limoges, France; University of Limoges, Limoges, France (Prof V Aboyans MD); Institute of Community and Public Health (Prof N M Abu-Rmeileh PhD), Birzeit University, Ramallah, Palestine; College of Medicine (O M Adebayo MD), Department of Community Medicine (O S Ilesanmi PhD), Department of Medicine (A S Oguntade MSc, Prof M O Owolabi DrM), University College Hospital, Ibadan, Ibadan, Nigeria; Social Behavioral Research Branch (S M Advani PhD), National Institute of Health, Bethesda, MD, USA; Department of Oncology (S M Advani PhD), Georgetown University, Washington, DC, USA; Department of Epidemiology and Biostatistics (M Aghaali PhD), Qom University of Medical Sciences, Qom, Iran; The Australian Centre for Public and Population Health Research (ACPPHR) (B O Ahinkorah MPH), School of Health (S Siabani PhD), University of Technology Sydney, Sydney, NSW, Australia; Faculty of Pharmacy (S Ahmad MSc), MAHSA University, Kuala Langat, Malaysia; Lincoln Medical School (K Ahmadi PhD), Universities of Nottingham & Lincoln, Lincoln, UK; Department of Biosciences (H Ahmed PhD), COMSATS Institute of Information Technology, Islamabad, Pakistan; Faculty of Medicine and Public Health (B Aji DrPH), Jenderal Soedirman University, Purwokerto, Indonesia; Department of Public Health (C J Akunna DMD), The Intercountry Centre for Oral Health (ICOH) for Africa, Jos, Nigeria; Department of Public Health (C J Akunna DMD), Federal Ministry of Health, Garki, Nigeria; John T Milliken Department of Internal Medicine (Z Al-Aly MD), Washington University in St Louis, St Louis, MO, USA; Clinical Epidemiology Center (Z Al-Aly MD), Department of Veterans Affairs, St Louis, MO, USA; Health Information Management and Technology Department (T M Alanzi PhD), Forensic Medicine Division (Prof R G Menezes MD), Department of Pharmacy Practice (A Naqvi PhD), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; Department of Cardiac Sciences (Prof K F Alhabib MD),

Internal Medicine Department (Y Mohammad MD), Pediatric Intensive Care Unit (M Temsah MD), King Saud University, Riyadh, Saudi Arabia; Department of Biological Sciences (L Ali PhD), Multidisciplinary Department (A Ullah MS), National University of Medical Sciences (NUMS), Rawalpindi, Pakistan; Epidemiology and Preventive Medicine (S M Alif PhD), Department of Epidemiology and Preventive Medicine (Prof Y Guo PhD, R M Islam PhD), School of Public Health and Preventive Medicine (S Li PhD), Monash University, Melbourne, VIC, Australia; Health Management and Economics Research Center (V Alipour PhD, J Arabloo PhD, S Azari PhD, A Ghashghaee BSc, M Hosseinzadeh PhD, A Rezapour PhD), Department of Health Economics (V Alipour PhD), Student Research Committee (A Ghashghaee BSc), Minimally Invasive Surgery Research Center (A Kabir MD), Preventive Medicine and Public Health Research Center (M Moradi-Lakeh MD), Iran University of Medical Sciences, Tehran, Iran (F Pashazadeh Kan BSN); Department of Health Policy and Management (Prof S M Aljunied PhD), Kuwait University, Safat, Kuwait; International Centre for Casemix and Clinical Coding (Prof S M Aljunied PhD), National University of Malaysia, Bandar Tun Razak, Malaysia; Bordeaux School of Public Health (Prof F Alla PhD), University of Bordeaux, Bordeaux, France; Department of Global Public Health (Prof P Allebeck MD), Department of Medical Epidemiology and Biostatistics (Prof J J Carrero PhD), Karolinska Institute, Stockholm, Sweden; Research Group in Hospital Management and Health Policies (Prof N Alvis-Guzman PhD), Universidad de la Costa (University of the Coast), Barranquilla, Colombia; Research Group in Health Economics (Prof N Alvis-Guzman PhD), University of Cartagena, Cartagena, Colombia; Public Health Department (Prof T T Amin MD), Cairo University, Cairo, Egypt; Department of Health Services Management (S Amini PhD), Department of Epidemiology (R Moradzadeh PhD, M Zamanian PhD), Department of Pediatrics (J Nazari MD), Arak University of Medical Sciences, Arak, Iran; Department of Population and Behavioural Sciences (H Amu PhD), University of Health and Allied Sciences, Ho, Ghana; Institute of Global Health (G H Amul MSc), University of Geneva, Geneva, Switzerland; Research for Impact, Singapore (G H Amul MSc); Pharmacy Department (Prof R Ancuceanu PhD), Department of Legal Medicine and Bioethics (S Hostiu PhD), Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Epidemiology and Biostatistics (Prof A Ansari-Moghaddam PhD), Zahedan University of Medical Sciences, Zahedan, Iran; Department of Health Policy and Administration (C T Antonio MD, E A Faraon MD), University of the Philippines Manila, Manila, Philippines; Department of Applied Social Sciences (C T Antonio MD), Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China; Menzies Institute for Medical Research (B Antony PhD, A Singh MTEch), University of Tasmania, Hobart, TAS, Australia; Department of Parasitology (D Anvari PhD), Mazandaran University of Medical Sciences, Sari, Iran; Department of Parasitology (D Anvari PhD), Iranshahr University of Medical Sciences, Iranshahr, Iran; Health Promotion Division (M Arora PhD), Health Policy Research (M R Mathur PhD), Public Health Foundation of India, Gurugram, India (Prof L Dandona MD, Prof R Dandona PhD, G Kumar PhD); Research Department (M Arora PhD), Health Related Information Dissemination Amongst Youth, New Delhi, India; Department of Plastic Surgery (M Asaad MD), University of Texas, Houston, TX, USA; School of Business (Prof M Ausloos PhD), University of Leicester, Leicester, UK; Department of Statistics and Econometrics (Prof M Ausloos PhD, Prof C Herteliu PhD, A Pana MD), Bucharest University of Economic Studies, Bucharest, Romania; School of Nursing and Health Sciences (A T Awan DrPH), Capella University, Minneapolis, MN, USA; Continuing Education Grant Writing Academy (A T Awan DrPH), University of Nevada, Las Vegas, NV, USA; School of Public Health (G Ayano MSc, T R Miller PhD), Curtin University, Perth, WA, Australia; Department of Clinical Midwifery (G L Aynalem MSc), Department of Biochemistry (M Derbew Molla MSc), Department of Surgical Nursing (A A Desta MSc), Department of Midwifery (B Kelkay MSc, A T Tamiru MSc), Department of Epidemiology and Biostatistics (Y Yeshaw MPH), University of Gondar, Gondar, Ethiopia; Kasturba Medical College, Mangalore (D B B MD, R Holla MD, P Rath MD),

- Manipal Institute of Management (S Nayak PhD), Department of Forensic Medicine and Toxicology (Prof V C Nayak MD), Manipal Academy of Higher Education, Manipal, India; Department of Forensic Science (A D Badiye MSc, N Kapoor MSc), Government Institute of Forensic Science, Nagpur, India; Unit of Biochemistry (A A Baig PhD), Faculty of Business and Management (M A Riaz Mcom), Universiti Sultan Zainal Abidin (Sultan Zainal Abidin University), Kuala Terengganu, Malaysia; Department of Anesthesiology (M Bakhshaei MD), Department of Cardiology (B Naghshtabrizi MD), Hamedan University of Medical Sciences, Hamadan, Iran; Department of Hypertension (Prof M Banach PhD), Medical University of Lodz, Lodz, Poland; Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland (Prof M Banach PhD); Department of Non-communicable Diseases (P C Banik MPhil), Bangladesh University of Health Sciences, Dhaka, Bangladesh; School of Psychology (Prof S L Barker-Collo PhD), University of Auckland, Auckland, New Zealand; Heidelberg Institute of Global Health (HIGH) (Prof T W Bärnighausen MD, S Chen DSc, S Mohammed PhD), Department of Ophthalmology (Prof J B Jonas MD, S Panda-Jonas MD), Heidelberg University, Heidelberg, Germany; T H Chan School of Public Health (Prof T W Bärnighausen MD, I Yunusa PhD), Center for Primary Care (S Basu PhD), Department of Global Health and Social Medicine (A W Eagan MSW), Department of Internal Medicine (N Rajai MD), Division of General Internal Medicine (Prof A Sheikh MD), Harvard University, Boston, MA, USA; Clinical Sciences Department (H J Barqawi MPhil), Department of Family and Community Medicine (B Saddik PhD), University of Sharjah, Sharjah, United Arab Emirates; School of Public Health (S Basu PhD, F Filippidis PhD), Department of Primary Care and Public Health (J Car PhD, F Greaves PhD, Prof A Majeed MD, R Palladino MD), Imperial College Business School (D Kusuma DSc), Imperial College London, London, UK; Health Human Resources Research Center (M Bayati PhD), Department of Epidemiology (M Dianatinasab MSc), Non-communicable Disease Research Center (Prof R Malekzadeh MD, S G Sepanlou MD), Department of Parasitology and Mycology (Prof K Pakshir PhD), Shiraz University of Medical Sciences, Shiraz, Iran; Department of Psychiatry (Prof S Bazargan-Hejazi BEP), Charles R Drew University of Medicine and Science, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences (Prof S Bazargan-Hejazi BEP), University of California Los Angeles, Los Angeles, CA, USA; Social Determinants of Health Research Center (M Behzadifar PhD), Lorestan University of Medical Sciences, Khorramabad, Iran; Department of Public Health (T T Bekuma MPH), Wollega University, Nekemte, Ethiopia; Nuffield Department of Population Health (D A Bennett PhD, B Lacey PhD), University of Oxford, Oxford, UK; Department of Internal Medicine (I M Bensenor PhD, Prof A R Brunoni PhD, A C Goulart PhD, I S Santos PhD), Department of Psychiatry (Prof A R Brunoni PhD, Prof J Castaldelli-Maia PhD), Center for Clinical and Epidemiological Research (A C Goulart PhD, I S Santos PhD), University of São Paulo, São Paulo, Brazil; Thoracic Surgery (K S S Berfield MD), Department of Veterans Affairs, Seattle, WA, USA; Department of Social and Clinical Pharmacy (A S Bhagavathula PharmD), Charles University, Hradec Kralova, Czech Republic; Institute of Public Health (A S Bhagavathula PharmD, I Elbarazi DrPH, Prof S M Shah PhD), United Arab Emirates University, Al Ain, United Arab Emirates; Department of Anatomy (Prof N Bhardwaj MD), Government Medical College Pali, Pali, India; Department of Community Medicine and Family Medicine (P Bhardwaj MD), School of Public Health (P Bhardwaj MD), Department of Forensic Medicine and Toxicology (T Kanchan MD), Department of Surgical Oncology (Prof S Misra MCh), All India Institute of Medical Sciences, Jodhpur, India; Department of Statistical and Computational Genomics (K Bhattacharyya MSc), National Institute of Biomedical Genomics, Kalyani, India; Department of Statistics (K Bhattacharyya MSc), University of Calcutta, Kolkata, India; Institute of Soil and Environmental Sciences (S Bibi PhD, S Ullah PhD), University of Agriculture, Faisalabad, Faisalabad, Pakistan; Social Determinants of Health Research Center (A Bijani PhD), Babol University of Medical Sciences, Babol, Iran; Department of Health Behaviour, Environment and Social Medicine (B Bintoro MD), Gadjah Mada University, Sleman, Indonesia; Department of General Surgery and Medical-Surgical Specialties (Prof A Biondi PhD, M Vacante PhD), University of Catania, Catania, Italy; Department of Public Health (S Birara MPH), Samara University, Samara, Ethiopia; Department of Epidemiology (D Braithwaite PhD), Pharmaceutical Outcomes and Policy Department (S O Nduaguba PhD), University of Florida, Gainesville, FL, USA; Cancer Population Sciences Program (D Braithwaite PhD), University of Florida Health Cancer Center, Gainesville, FL, USA; Division of Clinical Epidemiology and Aging Research (Prof H Brenner MD), German Cancer Research Center, Heidelberg, Germany; School of Public Health and Health Systems (Z A Butt PhD), University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public Health (Z A Butt PhD), Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan; Institute of Microengineering (F Caetano dos Santos PhD), Federal Polytechnic School of Lausanne, Lausanne, Switzerland; Internal Medicine Department (Prof L A Cámara MD), Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Board of Directors (Prof L A Cámara MD), Argentine Society of Medicine, Buenos Aires, Argentina (Prof P R Valdez MEd); Centre for Population Health Sciences (J Car PhD), Nanyang Technological University, Singapore; Department of Health Care (Prof R Cárdenas DSc), Metropolitan Autonomous University, Mexico City, Mexico; Oncological Network, Prevention and Research Institute (G Gorini MD), Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy (G Carreras PhD); College of Medicine (J Chang PhD), National Taiwan University, Taipei, Taiwan; Department of Nursing (J Chang PhD), National Taiwan University Hospital, Taipei, Taiwan; Center for Biomedicine and Community Health (D Chu PhD), VNU-International School, Hanoi, Vietnam; Department of Health Informatics (S Chung PhD), Department of Epidemiology and Public Health (Prof M Kivimäki PhD), Institute of Cardiovascular Science (A S Oguntade MSc), University College London, London, UK; Health Data Research UK, London, UK (S Chung PhD); Department of Public Health (Prof M Cirillo MD, R Palladino MD), University of Naples Federico II, Naples, Italy; Research Unit on Applied Molecular Biosciences (UCIBIO) (V M Costa PhD, J P Silva PhD), Department of Chemical Sciences (R A S Couto MD), Department of Chemistry (M Pinheiro PhD), University of Porto, Porto, Portugal; Department of Health Informatics (O Dadras DrPH), Graduate School of Medicine (O Dadras DrPH), Kyoto University, Kyoto, Japan; Faculty of Medicine (Prof A A M Damasceno PhD), Eduardo Mondlane University, Maputo, Mozambique; IRCCS Istituto Ortopedico Galeazzi (Galeazzi Orthopedic Institute IRCCS) (G Damiani MD), University of Milan, Milan, Italy; Department of Dermatology (G Damiani MD), Harrington Heart and Vascular Institute (A Guha MD), Case Western Reserve University, Cleveland, OH, USA; Indian Council of Medical Research, New Delhi, India (Prof L Dandona MD); Department of Pathology (P Daneshpajouhnejad MD), Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology (P Daneshpajouhnejad MD), Isfahan Cardiovascular Research Institute (Prof N Sarrafzadegan MD), Department of Radiology and Interventional Neuroradiology (O Shafaat MD), Isfahan University of Medical Sciences, Isfahan, Iran; Department of Public Health (J Darega Gela MPH), Ambo University, Ambo, Ethiopia; Health Research Institute (K Davletov PhD), Al Farabi Kazakh National University, Almaty, Kazakhstan; Department of Nursing (G A Dessie MSc), Department of Psychiatry (T B Mossie MSc, M Tareke MSc), College of Medicine and Health Sciences (G W Tsegaye MPH), Bahir Dar University, Bahir Dar, Ethiopia; Department of Community Medicine (Prof S D Dharmaratne MD), University of Peradeniya, Peradeniya, Sri Lanka; Department of Epidemiology and Biostatistics (M Dianatinasab MSc), Shahrood University of Medical Sciences, Shahrood, Iran; Center of Complexity Sciences (Prof D Diaz PhD), National Autonomous University of Mexico, Mexico City, Mexico; Faculty of Veterinary Medicine and Zootechnics (Prof D Diaz PhD), Autonomous University of Sinaloa, Culiacán Rosales, Mexico; Institute of Health Economics and Technology, Hanoi, Vietnam (H T Do MD); School of Population Health and Environmental Sciences (A Douiri PhD, Y Wang PhD), King's College London, London, UK; Postgraduate Program in Epidemiology (Prof B B Duncan PhD, Prof M I Schmidt PhD), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; School of Medicine (Prof A R Duraes PhD), Federal University of Bahia, Salvador, Brazil; Department of Internal Medicine (Prof A R Duraes PhD), Escola



Bahiana de Medicina e Saúde Pública (Bahiana School of Medicine and Public Health), Salvador, Brazil; Department of Social Services (A W Eagan MSW), Tufts Medical Center, Boston, MA, USA; Department of Epidemiology (M Ebrahimi Kalan MSc), Florida International University, Miami, FL, USA; College of Science, Health and Engineering (K Edvardsson PhD), La Trobe University, Bundoora, VIC, Australia; Pediatric Dentistry and Dental Public Health Department (Prof M El Tantawi PhD), Alexandria University, Alexandria, Egypt; Department of Physiology (S Esmailnejad PhD), Tarbiat Modares University, Tehran, Iran; Tehran Medical Sciences Branch (S Esmailnejad PhD), Islamic Azad University, Tehran, Iran; Division of Non-Communicable Diseases (I Fadhil PhD), Ministry of Public Health and Population, Dubai, United Arab Emirates; Dissemination Division (C S e Farinha MSc), National Institute of Statistics, Lisbon, Portugal; Activity Planning and Control Unit (C S e Farinha MSc), Directorate-General of Health (DGS), Lisbon, Portugal; Department of Cardiovascular Medicine (M Farwati MD), Mayo Clinic, Rochester, MN, USA; Non-communicable Diseases Research Center (Prof F Farzadfar DSc), Department of Environmental Health Engineering (M Fazlzadeh PhD, H Janjani PhD, Prof A Maleki PhD), School of Medicine (N Hafezi-Nejad MD), Digestive Diseases Research Institute (Prof R Malekzadeh MD, M Nalini MD, H Salimzadeh PhD, S G Sepanlou MD), Department of Epidemiology and Biostatistics (M Mansournia PhD), Sina Trauma and Surgery Research Center (Prof V Rahimi-Movaghar MD), Tehran University of Medical Sciences, Tehran, Iran; Department of Environmental Health Engineering (M Fazlzadeh PhD), Social Determinants of Health Research Center (T Zahirian Moghadam PhD, H Zandian PhD), Department of Community Medicine (H Zandian PhD), Ardabil University of Medical Science, Ardabil, Iran; National Institute for Stroke and Applied Neurosciences (Prof V L Feigin PhD), Auckland University of Technology, Auckland, New Zealand; Third Department of Neurology (E V Gnedovskaya PhD), Research Center of Neurology, Moscow, Russia (Prof V L Feigin PhD, Prof M A Piradov DSc); Vascular Surgery Department (C Fernandez Prendes MD), Ludwig Maximilians University, München, Germany; Vascular Surgery Department (C Fernandez Prendes MD), Department of Medical Sciences (Prof J Sundström PhD), Uppsala University, Uppsala, Sweden; Research Center on Public Health (P Ferrara MD), University of Milan Bicocca, Monza, Italy; Psychiatry Department (I Filip MD), Kaiser Permanente, Fontana, CA, USA; School of Health Sciences (I Filip MD), A T Still University, Mesa, AZ, USA; Institute of Gerontological Health Services and Nursing Research (F Fischer PhD), Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany; Sergio Arouca National School of Public Health, Rio de Janeiro, Brazil (L S Flor MPH); Federal University of Espírito Santo, Vitória, Brazil (L S Flor MPH); Institute of Gerontology (N A Foigt PhD), National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; Department of Child Dental Health (Prof M O Folayan FWACS), Obafemi Awolowo University, Ile-Ife, Nigeria; Department of Medical Parasitology (M Foroutan PhD), Abadan Faculty of Medical Sciences, Abadan, Iran; Gillings School of Global Public Health (M M Gad MD), Department of Epidemiology (J Y Islam PhD), University of North Carolina Chapel Hill, Chapel Hill, NC, USA; Department of Community Medicine (Prof A M Gaidhane MD), Datta Meghe Institute of Medical Sciences, Wardha, India; Department of Environmental Health Sciences (S Gallus DSc, A Lugo PhD), Mario Negri Institute for Pharmacological Research, Milan, Italy; Department of Public Health (B S Geberemariam MPH), Madda Walabu University, Bale Robe, Ethiopia; Department of Medical Surgical Nursing (M Ghafourifard PhD), School of Nursing and Midwifery (H Hassankhani PhD), School of Management and Medical Informatics (L R Kalankesh PhD), Social Determinants of Health Research Center (S Karimi PhD), Biotechnology Research Center (M Moghadaszadeh PhD), Molecular Medicine Research Center (M Moghadaszadeh PhD), Department of Biochemistry and Dietetics (S Pirouzpanah PhD), Tabriz University of Medical Sciences, Tabriz, Iran; Mount Auburn Hospital (A Ghajar MD), Harvard Medical School, Cambridge, MA, USA; Department of Cardiovascular Endocrine-metabolic Diseases and Aging (S Giampaoli MD), Istituto Superiore di Sanità (Italian National Institute of Health), Rome, Italy; Medical School (Prof P S Gill DM), University of

Warwick, Coventry, UK; Department of Social and Behavioural Sciences (F N Glozah PhD), University of Ghana, Accra, Ghana; Health Systems and Policy Research (M Golechha PhD), Indian Institute of Public Health Gandhinagar, Gandhinagar, India; Hudson College of Public Health (S V Gopalani MPH), University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Health and Social Affairs (S V Gopalani MPH), Government of the Federated States of Micronesia, Palikir, Federated States of Micronesia; Department of Respiratory Medicine (H Goudarzi PhD), Center for Environmental and Health Sciences (H Goudarzi PhD), Hokkaido University, Sapporo, Japan; Health Improvement Directorate (F Greaves PhD), Public Health England, London, UK; Division of Cardiovascular Medicine (A Guha MD), Ohio State University, Columbus, OH, USA; Department of Epidemiology (Prof Y Guo PhD), Binzhou Medical University, Yantai City, China; Department of Public Health (B Gupta PhD), Torrens University, Melbourne, VIC, Australia; Epidemiology and Biostatistics (R Gupta MPH), Department of Clinical Pharmacy and Outcomes Sciences (I Yunusa PhD), University of South Carolina, Columbia, SC, USA; Centre for Noncommunicable Diseases and Nutrition (R Gupta MPH), BRAC University, Dhaka, Bangladesh; Department of Preventive Cardiology (Prof R Gupta MD), Eternal Heart Care Centre & Research Institute, Jaipur, India; Department of Medicine (Prof R Gupta MD), Mahatma Gandhi University Medical Sciences, Jaipur, India; Department of Civil Engineering (Prof T Gupta DSc), Indian Institute of Technology Kanpur, Kanpur, India; Department of Radiology and Radiological Science (N Hafezi-Nejad MD, O Shafaat MD, S Sheikhbahaee MD), Department of Health Policy and Management (A T Khoja MD), Institute for Global Tobacco Control (K Welding PhD), Johns Hopkins University, Baltimore, MD, USA; Department of Social and Public Health (M Haider PhD), Ohio University, Athens, OH, USA; Department of Family and Community Medicine (Prof R R Hamadeh PhD), Arabian Gulf University, Manama, Bahrain; Medical School (Prof G J Hankey MD), University of Western Australia, Perth, WA, Australia; Department of Neurology (Prof G J Hankey MD), Sir Charles Gairdner Hospital, Perth, WA, Australia; Department of Epidemiology (A Hargono Dr), Faculty of Public Health (S Martini PhD), Universitas Airlangga (Airlangga University), Surabaya, Indonesia; Sekolah Tinggi Ilmu Kesehatan Indonesia Maju (Indonesian Advanced College of Health Sciences) (R K Hartono MPH), Institution of Public Health Sciences, Jakarta, Indonesia; Independent Consultant, Tabriz, Iran (H Hassankhani PhD, S N Irvani MD); Independent Consultant, Santa Clara, CA, USA (G Heidari MD); School of Business (Prof C Herteliu PhD), London South Bank University, London, UK; Department of Applied Microbiology (K Hezam PhD), Taiz University, Taiz, Yemen; Department of Microbiology (K Hezam PhD), Nankai University, Tianjin, China; Department for Health (T R Hird PhD), University of Bath, Bath, UK; Department of Pediatrics (M K Hole MD), University of Texas Austin, Austin, TX, USA; Clinical Legal Medicine Department (S Hostiu PhD), National Institute of Legal Medicine Mina Minovici, Bucharest, Romania; College of Science and Engineering (Prof M Househ PhD), Hamad Bin Khalifa University, Doha, Qatar; Jockey Club School of Public Health and Primary Care (J Huang MD, C Zhong MD), The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Health Promotion and Education (S E Ibitoye MPH), Department of Community Medicine (O S Ilesanmi PhD), Department of Medicine (Prof M O Owolabi DrM), University of Ibadan, Ibadan, Nigeria; Infectious Diseases Department (B Idrisov MD), Bashkir State Medical University, Ufa, Russia; Laboratory of Public Health Indicators Analysis and Health Digitalization (B Idrisov MD, S Soshnikov PhD), Moscow Institute of Physics and Technology, Moscow, Russia; Faculty of Medicine (I M Ilic PhD, Prof M M Santric-Milicevic PhD), School of Public Health and Health Management (Prof M M Santric-Milicevic PhD), University of Belgrade, Belgrade, Serbia; Department of Epidemiology (Prof M D Ilic PhD), Department of Global Health, Economics and Policy (Prof M Jakovljevic PhD), University of Kragujevac, Kragujevac, Serbia; Division of Community Health and Family Medicine (L R Inbaraj MD), Bangalore Baptist Hospital, Bangalore, India; Institute for Physical Activity and Nutrition (S Islam PhD), Deakin University, Burwood, VIC, Australia; Sydney Medical School (S Islam PhD), Save Sight Institute (H Kandel PhD), Menzies Centre for Health Policy

(F Sitas PhD), University of Sydney, Sydney, NSW, Australia; Surveillance and Health Services Research (F Islami PhD), American Cancer Society, Atlanta, GA, USA; Public Health Department of Social Medicine (Prof H Iso MD), Graduate School of Medicine (Prof K Yamagishi MD), Osaka University, Suita, Japan; Department of Health Management (R Itumalla PhD), University of Hail, Hail, Saudi Arabia; Department of Health Services Research (M Iwagami PhD), Research and Development Center for Health Services (Prof K Yamagishi MD), University of Tsukuba, Tsukuba, Japan; Department of Non-Communicable Disease Epidemiology (M Iwagami PhD), Medical Statistics Department (S Shivalli MD), London School of Hygiene & Tropical Medicine, London, UK; Department of Environmental Health Engineering (J Jaafari PhD), Guilan University of Medical Sciences, Rasht, Iran; Institute of Comparative Economic Studies (Prof M Jakovljevic PhD), Hosei University, Tokyo, Japan; Department of Preventive Medicine (Prof S Jang PhD), Yonsei University, Seodaemun-gu, South Korea; Substance Abuse Prevention Research Center (B Mansouri PhD), Social Development and Health Promotion Research Center (M Mirzaei-Alavijeh PhD), Cardiovascular Research Center (M Nalini MD), Research Center for Environmental Determinants of Health (K Sharafi PhD), Department of Health Education and Health Promotion (S Siabani PhD), Department of Sports Medicine and Rehabilitation (A Soroush MD), Kermanshah University of Medical Sciences, Kermanshah, Iran (H Janjani PhD); Department of Biochemistry (Prof S Jayaram MD), Government Medical College, Mysuru, India; Achutha Menon Centre for Health Science Studies (P Jeemon PhD), Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India; Department of Community Medicine (R P Jha MSc), Dr Baba Saheb Ambedkar Medical College & Hospital, Delhi, India; Department of Community Medicine (R P Jha MSc), Banaras Hindu University, Varanasi, India; Beijing Institute of Ophthalmology (Prof J B Jonas MD), Beijing Tongren Hospital, Beijing, China; Health Services Management Training Centre (T Joo MSc), Semmelweis University, Budapest, Hungary; Institute of Family Medicine and Public Health (M Jürisson PhD), University of Tartu, Tartu, Estonia; School of Public Health (Z Kabir PhD), University College Cork, Cork, Ireland; Sydney Eye Hospital (H Kandel PhD), South Eastern Sydney Local Health District, Sydney, NSW, Australia; MRC/CSO Social and Public Health Sciences Unit (S V Katikireddi PhD), University of Glasgow, Glasgow, UK; School of Pharmacy (H K Kebede MSc), Department of Psychiatry (M Soboka MSc), Jimma University, Jimma, Ethiopia; Institute for Global Tobacco Control, Baltimore, MD, USA (Prof R D Kennedy PhD); Department of Public Health (A T Khoja MD), Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia; Department of Public Health (Prof J Khubchandani PhD), New Mexico State University, Las Cruces, NM, USA; Department of Preventive Medicine (G Kim PhD, Prof E Park PhD), Institute of Health Services Research (D Lee BS, Prof E Park PhD), Department of Public Health (D Lee BS), Yonsei University, Seoul, South Korea; Big Data Department (Y Kim PhD), National Health Insurance Service, Wonju, South Korea; Department of Nutrition (R W Kimokoti MD), Simmons University, Boston, MA, USA; Department of Public Health (Prof M Kivimäki PhD), University of Helsinki, Helsinki, Finland (T J Meretoja MD); Independent Consultant, Jakarta, Indonesia (S Kosen MD); Kasturba Medical College, Udupi, India (S Koulmane Laxminarayana MD); CIBERSAM (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain (A Koyanagi MD); Department of Anthropology (K Krishan PhD), Panjab University, Chandigarh, India; University of Environment and Sustainable Development, Somanya, Ghana (N Kugbey PhD); Department of Community Medicine (N Kumar MD, R Thapar MD), Manipal Academy of Higher Education, Mangalore, India; Faculty of Health and Life Sciences (O P Kurmi PhD), Coventry University, Coventry, UK; Department of Medicine (O P Kurmi PhD), Department of Psychiatry and Behavioural Neurosciences (A T Olagunju MD), McMaster University, Hamilton, ON, Canada; Faculty of Public Health (D Kusuma DSc), University of Indonesia, Depok, Indonesia; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK (B Lacey PhD); Division of Research (J O Lam PhD),

Kaiser Permanente, Oakland, CA, USA; Unit of Genetics and Public Health (Prof I Landires MD), Institute of Medical Sciences, Las Tablas, Panama; Ministry of Health, Herrera, Panama (Prof I Landires MD); Department of Otorhinolaryngology (S Lasrado MS), Father Muller Medical College, Mangalore, India; Institute of Clinical Physiology (P Lauriola MD), National Research Council, Pisa, Italy; Graduate School of Public Health (Y Lee PhD), Ajou University, Suwon-si, South Korea; Center for Youth Substance Abuse Research (J Leung PhD), The University of Queensland, St Lucia, QLD, Australia; School of Public Health (Prof H Lin PhD), Zhengzhou University, Zhengzhou, China; School of Public Health (Prof S Linn DrPH), University of Haifa, Haifa, Israel; Institute for Health and Environment (W Liu PhD), Chongqing University of Science and Technology, Chongqing, China; Melbourne School of Population and Global Health (Prof A D Lopez PhD), School of Health Sciences (A Meretoja MD), Department of Pediatrics (Prof G C Patton MD), Department of General Practice (J Zhang MD), University of Melbourne, Melbourne, VIC, Australia; Department of Epidemiology and Evidence Based Medicine (P D Lopukhov PhD), Department of Epidemiology and Evidence-Based Medicine (R V Polibin PhD), I M Sechenov First Moscow State Medical University, Moscow, Russia; Institute of Nutritional Sciences (Prof S Lorkowski PhD), Friedrich Schiller University Jena, Jena, Germany; Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany (Prof S Lorkowski PhD); Environmental Health Research Center (Prof A Maleki PhD), Social Determinants of Health Research Center (G Moradi PhD), Department of Epidemiology and Biostatistics (G Moradi PhD), Kurdistan University of Medical Sciences, Sanandaj, Iran; Department of Maternal and Child Nursing and Public Health (Prof D C Malta PhD), Federal University of Minas Gerais, Belo Horizonte, Brazil; Institute for Social Science Research (A A Mamun PhD), The University of Queensland, Indooroopilly, QLD, Australia; Department of Psychiatry (N Manjunatha MD), National Institute of Mental Health and Neurosciences, Bangalore, India; Psychiatry Department (J Martinez-Raga PhD), Hospital Universitario Doctor Peset, Valencia, Spain; Department of Medicine (J Martinez-Raga PhD), University of Valencia, Valencia, Spain; Indonesian Public Health Association, Surabaya, Indonesia (S Martini PhD); Institute of Population Health Sciences (M R Mathur PhD), University of Liverpool, Liverpool, UK; Department of Dentistry (C E Medina-Solis MSc), Autonomous University of Hidalgo State, Pachuca, Mexico; Ministry of Health, Kathmandu, Nepal (S Mehata PhD); Peru Country Office (W Mendoza MD), United Nations Population Fund (UNFPA), Lima, Peru; Neurology Unit (A Meretoja MD), Breast Surgery Unit (T J Meretoja MD), Helsinki University Hospital, Helsinki, Finland; Center for Innovation in Medical Education (B Miazgowski MD), Pomeranian Medical University, Szczecin, Poland (B Miazgowski MD); Woman-Mother-Child Department (I Michalek PhD), Lausanne University Hospital, Lausanne, Switzerland; Pacific Institute for Research & Evaluation, Calverton, MD, USA (T R Miller PhD); Internal Medicine Programme (Prof E M Mirrakhimov PhD), Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease (Prof E M Mirrakhimov PhD), National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan; Research Center for Biochemistry and Nutrition in Metabolic Diseases (H Mirzaei PhD), Kashan University of Medical Sciences, Kashan, Iran; Department of Epidemiology and Biostatistics (A Mohammadian-Hafshejani PhD), Shahrekord University of Medical Sciences, Shahrekord, Iran; Health Systems and Policy Research Unit (S Mohammed PhD), Department of Surgery (M A Tolani FWACS), Ahmadu Bello University, Zaria, Nigeria; Clinical Epidemiology and Public Health Research Unit (L Monasta DSc, L Ronfani PhD), Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; World Health Organization (WHO) Centre on eHealth (M Moni PhD), School of Public Health and Community Medicine (Prof A E Schutte PhD), Centre for Primary Health Care and Equity (CPHCE) (F Sitas PhD), University of New South Wales, Sydney, NSW, Australia; Section of Plastic Surgery (S D Morrison MD), University of Michigan School of Medicine, Ann Arbor, MI, USA; Department of Epidemiology and Biostatistics (S Mubarik MS, Prof C Yu PhD), School of Medicine (Z Zhang PhD), Wuhan University, Wuhan, China; Department of Pulmonary Medicine (S Nair MD), Government Medical



College Trivandrum, Trivandrum, India; Health Action by People, Trivandrum, India (S Nair MD); Suraj Eye Institute, Naggur, India (V Nangia MD); Discipline of Social & Administrative Pharmacy (A Naqvi PhD), University of Science, Malaysia, Penang, Malaysia; Mysore Medical College and Research Institute (Prof S Narasimha Swamy MD), Government Medical College, Mysore, India; Department of Biotechnology (M Naveed PhD), University of Central Punjab, Lahore, Pakistan; Bupa Clemton Park (S Neupane Kandel BSN), Bupa, Sydney, NSW, Australia; Institute for Global Health Innovations (C T Nguyen MPH, H L T Nguyen MPH), Duy Tan University, Hanoi, Vietnam; Center of Excellence in Behavioral Medicine (S H Nguyen BS, T H Nguyen BMedSc, G T Vu BA), Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam; Unit on Risk and Resilience in Mental Disorders (Prof D J Stein MD), South African Medical Research Council, Cape Town, South Africa (C A Nnaji MPH); School of Public Health and Family Medicine (C A Nnaji MPH), Department of Paediatrics & Child Health (Prof H J Zar PhD), University of Cape Town, Cape Town, South Africa; Department of Clinical Sciences (Prof B Norrving PhD), Lund University, Lund, Sweden; Centre for Heart Rhythm Disorders (J Noubiap MD), University of Adelaide, Adelaide, SA, Australia; Department of Neurobiology, Care Sciences and Society (C Nowak PhD), Karolinska Institute, Huddinge, Sweden; Translational Health Research Institute (F A Ogbo PhD), Western Sydney University, Sydney, NSW, Australia; Department of Preventive Medicine (I Oh PhD), Kyung Hee University, Dongdaemun-gu, South Korea; Department of Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; Graduate School of Public Health (Prof E Oren PhD), San Diego State University, San Diego, CA, USA; Laboratory of Public Health Indicators Analysis and Health Digitalization (N Oststavnov BA, S S Oststavnov PhD), Moscow Institute of Physics and Technology, Dolgoprudny, Russia; Department of Project Management (S S Oststavnov PhD), National Research University Higher School of Economics, Moscow, Russia; Department of Respiratory Medicine (Prof M P A DNB), Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India; Department of Medicine (S Pakhale MD), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Health Metrics (A Pana MD), Center for Health Outcomes & Evaluation, Bucharest, Romania; Research Department (A Pandey MPH), Nepal Health Research Council, Kathmandu, Nepal; Research Department (A Pandey MPH), Public Health Research Society Nepal, Kathmandu, Nepal; Department of Forensic Medicine & Toxicology (U Parekh MD), Pramukhswami Medical College, Anand, India; Department of Medical Humanities and Social Medicine (Prof E Park PhD), Kosin University, Busan, South Korea; Population Health Theme (Prof G C Patton MD), Murdoch Childrens Research Institute, Melbourne, VIC, Australia; Department of Genetics (S Pawar PhD), Department of Internal Medicine (R Shrestha PhD), Yale University, New Haven, CT, USA; Pennsylvania Cancer and Regenerative Medicine Center (R G Pestell MD), Baruch S Blumberg Institute, Doylestown, PA, USA; Department of Medicine (R G Pestell MD), Xavier University School of Medicine, Woodbury, NY, USA; HIV and Mental Health Department (K N Pokhrel PhD), Integrated Development Foundation Nepal, Kathmandu, Nepal; Department of Biochemistry (Prof A Prashant PhD), Jagadguru Sri Shivarathreeswara University, Mysuru, India; Health Sciences Department (D R A Pribadi MSc), Muhammadiyah University of Surakarta, Sukoharjo, Indonesia; College of Medicine (A Radfar MD), University of Central Florida, Orlando, FL, USA; Data Mining Research Unit (DaMRA) (A Rahman PhD), Charles Sturt University, Wagga Wagga, NSW, Australia; Department of Community Medicine (M Rahman PhD), Maharishi Markandeshwar Medical College & Hospital, Solan, India; School of Nursing and Healthcare Professions (M Rahman PhD), Federation University Australia, Berwick, VIC, Australia; School of Nursing and Midwifery (M Rahman PhD), La Trobe University, Melbourne, VIC, Australia; Future Technology Research Center (A Rahmani PhD), National Yunlin University of Science and Technology, Yunlin, Taiwan; Institute of Research and Development (A Rahmani PhD), Duy Tan University, Da Nang, Vietnam; Department of Cardiology (P Ram MD), Emory University, Atlanta, GA, USA; Research Department (C L Ranabhat PhD), Policy Research Institute, Kathmandu, Nepal; Health and Public Policy Department

(C L Ranabhat PhD), Global Center for Research and Development, Kathmandu, Nepal; School of Health, Medical and Applied Sciences (L Rawal PhD), CQ University, Sydney, NSW, Australia; School of Social Sciences and Psychology (Prof A M N Renzaho PhD), Translational Health Research Institute (Prof A M N Renzaho PhD), Western Sydney University, Penrith, NSW, Australia; Department of Tobacco Research (L M Reynales-Shigematsu PhD, L Zavala-Arciniega MSc), National Institute of Public Health, Cuernavaca, Mexico; Cardiovascular Diseases Research Center (S Riahi PhD), Birjand University of Medical Sciences, Birjand, Iran; Department of Clinical Research (L Roever PhD), Federal University of Uberlândia, Uberlândia, Brazil; Golestan Research Center of Gastroenterology and Hepatology (GRCGH) (G Roshandel PhD), Golestan University of Medical Sciences, Gorgan, Iran; Department of Cardiology (Prof A Roy MD), All India Institute of Medical Sciences, New Delhi, India; Faculty of Medicine (B Roy PhD), Quest International University Perak, Ipoh, Malaysia; Department of Neurology (Prof S Sacco MD), University of L'Aquila, L'Aquila, Italy; Applied Biomedical Research Center (A Sahebkar PhD), Biotechnology Research Center (A Sahebkar PhD), Mashhad University of Medical Sciences, Mashhad, Iran; Emergency Department (M Samaei MD), Brown University, Providence, RI, USA; Department of Entomology (A M Samy PhD), Neurology Department (Prof A S Shalash PhD), Ain Shams University, Cairo, Egypt; School of Population and Public Health (Prof N Sarrafzadegan MD), University of British Columbia, Vancouver, BC, Canada; Department of Geriatrics and Long Term Care (B Sathian PhD), Hamad Medical Corporation, Doha, Qatar; Faculty of Health & Social Sciences (B Sathian PhD), Bournemouth University, Bournemouth, UK; Department of Public Health Sciences (M Sawhney PhD), University of North Carolina at Charlotte, Charlotte, NC, USA; Market Access (M Saylan MD), Bayer, Istanbul, Turkey; Swiss Research Institute for Public Health and Addiction (M P Schaub PhD), University of Zürich, Zurich, Switzerland; Department of Health Sciences (I J C Schneider PhD), Federal University of Santa Catarina, Araranguá, Brazil; The George Institute for Global Health, Sydney, NSW, Australia (Prof A E Schutte PhD, Prof J Sundström PhD); Oral Diagnosis, Digital Health and Health Services Research (Prof F Schwendicke PhD), Charité University Medical Center Berlin, Berlin, Germany; Department of Population and Health (A Seidu Mphil), University of Cape Coast, Cape Coast, Ghana; College of Public Health, Medical and Veterinary Sciences (A Seidu Mphil), James Cook University, Townsville, QLD, Australia; Department of Biotechnology (Prof N Senthil Kumar PhD), Mizoram University, Aizawl, India; National Heart, Lung, and Blood Institute (A Seylani BS), National Institute of Health, Rockville, MD, USA; Family Medicine (Prof S M Shah PhD), Aga Khan University, Karachi, Pakistan; Independent Consultant, Karachi, Pakistan (M A Shaikh MD); Department of Community Medicine (M Shannawaz PhD), BLDE University, Vijayapur, India; Centre for Medical Informatics (Prof A Sheikh MD), University of Edinburgh, Edinburgh, UK; National Institute of Infectious Diseases, Tokyo, Japan (M Shigematsu PhD); Finnish Institute of Occupational Health, Helsinki, Finland (R Shiri PhD); Washington State University, Pullman, WA, USA (K Shishani PhD); Public Health Dentistry Department (Prof K M Shivakumar PhD), Krishna Institute of Medical Sciences Deemed to be University, Karad, India; Department of Public Health (N B Sidemo MPH), Department of Biomedical Sciences (E G Tadesse MSc), Arba Minch University, Arba Minch, Ethiopia; Department of Psychology (Prof I D Sigfusdottir PhD, R Sigurvinsdottir PhD), Reykjavik University, Reykjavik, Iceland; Department of Health and Behavior Studies (Prof I D Sigfusdottir PhD), Columbia University, New York, NY, USA; Department of Physical Education (Prof D A S Silva PhD), Federal University of Santa Catarina, Florianópolis, Brazil; School of Medicine (Prof J A Singh MD), University of Alabama at Birmingham, Birmingham, AL, USA; Medicine Service (Prof J A Singh MD), US Department of Veterans Affairs, Birmingham, AL, USA; Department of Pulmonary Medicine (Prof V Singh MD), Asthma Bhawan, Jaipur, India; Department of Epidemiology (D N Sinha PhD), School of Preventive Oncology, Patna, India; Department of Epidemiology (D N Sinha PhD), Healis Sekhsaria Institute for Public Health, Mumbai, India; Department No 16 (V Y Skryabin MD), Laboratory of Genetics and Genomics

(Prof M S Zastrozhin PhD), Moscow Research and Practical Centre on Addictions, Moscow, Russia; Therapeutic Department (A A Skryabina MD), Balashiha Central Hospital, Balashikha, Russia; Hospital Universitario de La Princesa (Princess University Hospital) (Prof J B Soriano MD), Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES) (Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain (Prof J B Soriano MD); Institute for Leadership and Health Management (S Soshnikov PhD), Sechenov First Moscow State Medical University, Moscow, Russia; Hull York Medical School (I N Soyiri PhD), University of Hull, Hull City, UK; Division of Community Medicine (C T Sreeramareddy MD), International Medical University, Kuala Lumpur, Malaysia; Department of Medicine (P Steiropoulos MD), Democritus University of Thrace, Alexandroupolis, Greece; Department of Cardiology (S Storteky MD), University of Bern, Bern, Switzerland; Schiller Institute (Prof K Straif PhD), Boston College, Boston, MA, USA; Barcelona Institute for Global Health, Barcelona, Spain (Prof K Straif PhD); Department of Statistics (R Suliankatchi Abdulkader MD), Manonmaniam Sundaranar University, Abishekapatti, India; National Institute of Epidemiology (R Suliankatchi Abdulkader MD), Indian Council of Medical Research, Chennai, India; Norwegian Institute of Public Health, Bergen, Norway (G Sulo PhD); Cancer Control Center (T Tabuchi MD), Osaka International Cancer Institute, Osaka, Japan; School of Dentistry and Oral Health (S K Tadakamadla PhD), Griffith University, Gold Coast, QLD, Australia; Department of Pharmacy (B W Taddele MPH), Arbaminch College of Health Sciences, Arba Minch, Ethiopia; Department of Population Science and Human Resource Development (Prof M I Tareque PhD), University of Rajshahi, Rajshahi, Bangladesh; Research and Development Center for Humanities and Health Management (I U Tarigan PhD), National Institute of Health Research & Development, Jakarta, Indonesia; Department of Public Health and Community Medicine (Prof K R Thankappan MD), Central University of Kerala, Kasaragod, India; Faculty of Biomedical Engineering (A Tichopad PhD), Czech Technical University, Prague, Czech Republic; 1st Department of Ophthalmology (Prof F Topouzis PhD), Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Pathology and Legal Medicine (M R Tovani-Palone PhD), University of São Paulo, Ribeirão Preto, Brazil; Modestum, London, UK (M R Tovani-Palone PhD); Department of Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, Vietnam; Department of Community Medicine (J P Tripathy MD), All India Institute of Medical Sciences, Nagpur, India; Department of Vascular Surgery (N Tsilimparis PhD), Ludwig Maximilians University, Munich, Germany; Department of Cardiovascular, Endocrine-metabolic Diseases and Aging (B Unim PhD), National Institute of Health, Rome, Italy; Velez Sarsfield Hospital, Buenos Aires, Argentina (Prof P R Valdez MD); Laboratory of Toxicology (C Vardavas PhD), University of Crete, Heraklion, Greece; Epidemiology Department (Prof P Varona Pérez MSc), National Institute of Hygiene, Epidemiology and Microbiology (INHEM), Havana, Cuba; UKK Institute, Tampere, Finland (Prof T J Vasankari MD); Raffles Neuroscience Centre (Prof N Venketasubramanian MBBS), Raffles Hospital, Singapore; Yong Loo Lin School of Medicine (Prof N Venketasubramanian MBBS), National University of Singapore, Singapore; Department of Community Medicine and Family Medicine (M Verma MD), All India Institute of Medical Sciences, Bathinda, India; Department of Psychopharmacology (M V Vetrova MD), Pavlov University, Saint Petersburg, Russia; Faculty of Information Technology (B Vo PhD), Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City, Vietnam; Foundation University Medical College (Prof Y Waheed PhD), Foundation University Islamabad, Islamabad, Pakistan; Demographic Change and Aging Research Area (A Werdecker PhD), Federal Institute for Population Research, Wiesbaden, Germany; Department of Community Medicine (N D Wickramasinghe MD), Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka; Division of Cardiology (S Yandrapalli MD), New York Medical College, Valhalla, NY, USA; Division of Cardiology (S Yandrapalli MD), Westchester Medical Center, Valhalla, NY, USA; Department of Public Health (Prof H Yatsuya PhD), Fujita Health University, Toyoake, Japan; Department of Public Health and Health Systems (Prof H Yatsuya PhD), Nagoya University, Nagoya, Japan;

Health Services Management Research Center (V Yazdi-Feyzabadi PhD), Department of Health Management, Policy, and Economics (V Yazdi-Feyzabadi PhD), Kerman University of Medical Sciences, Kerman, Iran; Human Anatomy Unit (M Z Yimmer MSc), Wollo University, Dessie, Ethiopia; Department of Neuropsychopharmacology (N Yonemoto MPH), National Center of Neurology and Psychiatry, Kodaira, Japan; Department of Public Health (N Yonemoto MPH), Juntendo University, Tokyo, Japan; Department of Health care Management and Economics (H Yusefzadeh PhD), Urmia University of Medical Science, Urmia, Iran; School of Rehabilitation Therapy (M S Zaman MSc), Queen's University, Kingston, ON, Canada; Unit on Child & Adolescent Health (Prof H J Zar PhD), Medical Research Council South Africa, Cape Town, South Africa; Addictology Department (Prof M S Zastrozhin PhD), Pediatrics Department (A Zastrozhina PhD), Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia (J Zhang MD); Health Technology Assessment Unit (Y H Zuniga BS), Department of Health Philippines, Manila, Philippines; #MentalHealthPH, Quezon City, Philippines (Y H Zuniga BS).

#### Declaration of interests

ViA reports personal fees from Bayer Healthcare, Boehringer Ingelheim/Lilly alliance, Bristol Myers Squibb/Pfizer alliance, and Novo Nordisk outside of the submitted work. RA reports consultancy and speakers' fees from UCB, Sandoz, AbbVie, Zentiva, Teva, Laropharm, CEGEDIM, Angelini, Biessen Pharma, Hofigal, AstraZeneca, and Stada outside of the submitted work. BeA reports personal fees from Australian Institute of Sports; non-financial support from Zydus Cadila; and grants and non-financial support from Natural Remedies outside of the submitted work. FG was employed by Public Health England during the conduct of the study, which does not necessarily endorse this study. GJH reports personal fees from the American Heart Association outside of the submitted work. SMSI reports grants from National Heart Foundation of Australia and from the Australian National Health and Medical Research Council (NHMRC) outside of the submitted work. SVK reports grants from Chief Scientist Office and UK Medical Research Council during the conduct of the study. KK reports non-financial support from UGC Centre of Advanced Study (CAS II), Department of Anthropology, Panjab University, Chandigarh, India, outside of the submitted work. StL reports personal fees from Akcea Therapeutics, Amedes, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo, Lilly, MSD Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Synlab, Unilever, and Upfield, and non-financial support from Preventicus outside of the submitted work. WM is Program Analyst in Population and Development at the UN Population Fund-UNFPA Country Office in Peru, which does not necessarily endorse this study. TRM reports contracts from Gov't Plaintiff Lawyers, JUUL, outside of the submitted work. BoN reports personal fees from AstraZeneca and Bayer, outside of the submitted work. SimS reports grants, personal fees, and non-financial support from Abbott and Novartis; personal fees and non-financial support from Allergan-Abbvie, AstraZeneca, and Teva; and personal fees from Eli Lilly and Novo Nordisk outside of the submitted work. AES reports personal fees from Takeda, Novartis, Servier, and Omron Healthcare outside of the submitted work. JAS reports consultancy fees from Crealta/Horizon, Medisys, Fidia, Two Labs Inc, Adept Field Solutions, Clinical Care options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, UBM, Trio Health, Medscape, WebMD, Practice Point communications, the National Institutes of Health, and the American College of Rheumatology; payment for lectures including service on Simply Speaking speaker's bureau; and stock ownership in TPT Global Tech, Vaxart pharmaceuticals, and Charlotte's Web Holdings. JAS previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals; held placement on the steering committee of OMERACT, an international organisation that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies; serves on the US Food and Drug Administration Arthritis Advisory Committee; is a member of the Veterans Affairs Rheumatology Field Advisory Committee; and is the editor and the director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis.

DJS reports personal fees from Lundbeck, Takeda, Johnson & Johnson, and Servier outside of the submitted work. StS reports grants from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott; and personal fees from Boston Scientific, Teleflex, and BTG outside of the submitted work. JS reports ownership in companies providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer, and AstraZeneca outside of the submitted work. FT reports grants and personal fees from Novartis, Thea, Alcon, Pfizer, and Bayer; grants from Bausch & Lomb; and personal fees from Allergan, Omikron, and Santen outside of the submitted work. All other authors declare no competing interests.

#### Data sharing

To download the data used in these analyses, please visit the Global Health Data Exchange GBD 2019 website.

#### Acknowledgments

SheMA acknowledges support from Monash University, VIC, Australia. SYMA would like to acknowledge the International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia and Department of Health Policy and Management, Faculty of Public Health, Kuwait University for the approval and support to participate in this research project. MarA, AdP, and CH are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation (CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084). TWB was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. SB-H was supported by National Institutes of Health (NIH) National Center for Advancing Translational Science (NCATS) UCLA (CTSI grant number UL1TR001881). DAB research receives support from the Oxford National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). VMC acknowledges her grant (SFRH/BHD/110001/2015), received by Portuguese national funds through Fundação para a Ciência e Tecnologia (FCT), IP, under the Norma Transitória DL57/2016/CP1334/CT0006. AD acknowledges funding support from the NIHR Applied Research Collaboration (ARC) South London at King's College Hospital NHS Foundation Trust and the Royal College of Physicians, as well as the support from the NIHR BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College London. MEK was supported by FIU University Graduate School Dissertation Year Fellowship. PSG is supported by the NIHR Applied Research Collaborations West Midlands; the NIHR Global Health Research Unit on Improving Health in Slums at the University of Warwick; and the NIHR Global Health Group on Addressing Smokeless Tobacco Use & Building Research Capacity in South Asia at the University of York. CH and AdP are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation (CNDS-UEFISCDI, project number PN-III-P2-2.1-SOL-2020-2-0351). JYI is supported by UNC's Cancer Care Quality Training 2T32CA116339-11. SMSI is funded by the National Heart Foundation of Australia and NHMRC. MihJ acknowledges funding through grant OI 175 014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. PJ acknowledges the Wellcome Trust/DBT India Alliance Fellowship support (IA/CPH1/14/1/501497). HK acknowledges being the Kornhauser Research Associate at The University of Sydney, Save Sight Institute. SVK acknowledges funding from a NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC\_UU\_00022/2) and the Scottish Government Chief Scientist Office (SPHSU13). SLKL acknowledges support by the Manipal Academy of Higher Education. KK is supported by the UGC Centre of Advanced Study (CAS II) awarded to the Department of Anthropology, Panjab University, Chandigarh, India. BL acknowledges support from UK Biobank, the NIHR Oxford BRC, and the BHF Oxford Centre of Research Excellence. IL is member of the Sistema Nacional de Investigación (SNI), which is supported by the Secretaría Nacional de Ciencia, Tecnología e Innovación (SENACYT), Panamá. StL acknowledges institutional support from the Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig (Germany; German Federal Ministry of Education and Research; grant agreement number 01EA1808A). RGP is supported in part by funding from the

NIH National Cancer Institute (R01CA132115, R21CA235139-01) and the Breast Cancer Research Program (W81XWH1810605, Breakthrough Award) from the Department of Defense. PriR acknowledges the Manipal Academy of Higher Education, Manipal. AMS acknowledges the support from a fellowship from the Egyptian Fulbright Mission Program. MMS-M acknowledges the support of the Ministry of Education, Science and Technological Development of the Republic of Serbia (contract number 175087). AzS acknowledges support from the HDRUK BREATHE Hub. JPS acknowledges support from Applied Molecular Biosciences Unit (UCIBIO; grant number UIDB/04378/2020), supported through Portuguese national funds via FCT/MCTES. AmbS is supported by the International Graduate Research Scholarship, University of Tasmania. JBS is part of the Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. SKT acknowledges support from an NHMRC Early Career Fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Editorial note: the *Lancet* Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

#### References

- GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**: 1223–49.
- Goodchild M, Nargis N, Tursan d'Espaignet E. Global economic cost of smoking-attributable diseases. *Tob Control* 2018; **27**: 58–64.
- Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. *N Engl J Med* 2014; **370**: 60–68.
- US National Cancer Institute, WHO. Monograph 21. The economics of tobacco and tobacco control; NIH Publication No. 16-CA-8029A. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2016. [https://cancercontrol.cancer.gov/sites/default/files/2020-06/m21\\_complete.pdf](https://cancercontrol.cancer.gov/sites/default/files/2020-06/m21_complete.pdf) (accessed April 9, 2021).
- Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964–2012. *JAMA* 2014; **311**: 164–71.
- Lightwood J, Glantz SA. Smoking behavior and healthcare expenditure in the United States, 1992–2009: panel data estimates. *PLoS Med* 2016; **13**: e1002020.
- van Meijgaard J, Fielding JE. Estimating benefits of past, current, and future reductions in smoking rates using a comprehensive model with competing causes of death. *Prev Chronic Dis* 2012; **9**: E122.
- WHO. WHO framework convention on tobacco control. Geneva: World Health Organization, 2005.
- Chung-Hall J, Craig L, Gravely S, Sansone N, Fong GT. Impact of the WHO FCTC over the first decade: a global evidence review prepared for the Impact Assessment Expert Group. *Tob Control* 2019; **28** (suppl 2): s119–28.
- WHO. WHO report on the global tobacco epidemic 2019: offer help to quit tobacco use. Geneva: World Health Organization, 2019. <https://www.who.int/teams/health-promotion/tobacco-control/who-report-on-the-global-tobacco-epidemic-2019> (accessed April 28, 2021).
- WHO Regional Office for South-East Asia. Tobacco control for sustainable development. New Delhi: World Health Organization, Regional Office for South-East Asia, 2017. <https://apps.who.int/iris/handle/10665/255509> (accessed April 9, 2021).
- Beaglehole R, Bonita R, Alleyne G, et al. UN High-Level meeting on non-communicable diseases: addressing four questions. *Lancet* 2011; **378**: 449–55.
- Bennett JE, Kontis V, Mathers CD, et al. NCD countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. *Lancet* 2020; **396**: 918–34.
- Sacco RL, Roth GA, Reddy KS, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation. *Circulation* 2016; **133**: e674–90.

For the Global Health Data Exchange GBD 2019 website see <http://ghdx.healthdata.org/gbd-2019/data-input-sources>

- 15 Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. *Lancet* 2012; **379**: 1269–71.
- 16 Beaglehole R, Bonita R, Horton R, et al. Measuring progress on NCDs: one goal and five targets. *Lancet* 2012; **380**: 1283–85.
- 17 Bilano V, Gilmour S, Moffiet T, et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. *Lancet* 2015; **385**: 966–76.
- 18 Doll R. On the aetiology of cancer of the lung. *Acta Unio Int Contra Cancrum* 1951; **7**: 39–50.
- 19 Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. *JAMA* 2014; **311**: 183–92.
- 20 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet* 2017; **389**: 1885–906.
- 21 Hoffman SJ, Mammone J, Rogers Van Katwyk S, et al. Cigarette consumption estimates for 71 countries from 1970 to 2015: systematic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions. *BMJ* 2019; **365**: 12231.
- 22 Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet* 1997; **349**: 1436–42.
- 23 Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. *Lancet* 1992; **339**: 1268–78.
- 24 Ezzati M, Lopez AD. Measuring the accumulated hazards of smoking: global and regional estimates for 2000. *Tob Control* 2003; **12**: 79–85.
- 25 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet* 2016; **388**: e19–23.
- 26 GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet Public Health* 2021; published online May 27. [https://doi.org/S2468-2667\(21\)00065-7](https://doi.org/S2468-2667(21)00065-7).
- 27 GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1923–94.
- 28 Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr* 2012; **10**: 1.
- 29 Flaxman AD, Vs T, Murray CJL. An integrative metaregression framework for descriptive epidemiology. University of Washington Press. <https://uwapress.uw.edu/book/9780295991849/an-integrative-metaregression-framework-for-descriptive-epidemiology> (accessed June 17, 2020).
- 30 Reitsma M, Kendrick P, Anderson J, et al. Reexamining rates of decline in lung cancer risk after smoking cessation. A meta-analysis. *Ann Am Thorac Soc* 2020; **17**: 1126–32.
- 31 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**: 1204–22.
- 32 Hanley JA. A heuristic approach to the formulas for population attributable fraction. *J Epidemiol Community Health* 2001; **55**: 508–14.
- 33 Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. *BMJ* 1950; **2**: 739–48.
- 34 Gravelly S, Giovino GA, Craig L, et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. *Lancet Public Health* 2017; **2**: e166–74.
- 35 Hammond D. Health warning messages on tobacco products: a review. *Tob Control* 2011; **20**: 327–37.
- 36 Henriksen L. Comprehensive tobacco marketing restrictions: promotion, packaging, price and place. *Tob Control* 2012; **21**: 147–53.
- 37 Levy DT, Tam J, Kuo C, Fong GT, Chaloupka F. The impact of implementing tobacco control policies: the 2017 tobacco control policy scorecard. *J Public Health Manag Pract* 2018; **24**: 448–57.
- 38 Chaloupka FJ, Straif K, Leon ME. Effectiveness of tax and price policies in tobacco control. *Tob Control* 2011; **20**: 235–38.
- 39 WHO. Earmarked tobacco taxes: lessons learnt from nine countries. Geneva: World Health Organization, 2016. [https://apps.who.int/iris/bitstream/handle/10665/206007/9789241510424\\_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/206007/9789241510424_eng.pdf?sequence=1) (accessed April 9, 2021).
- 40 Dresler CM, León ME, Straif K, Baan R, Secretan B. Reversal of risk upon quitting smoking. *Lancet* 2006; **368**: 348–49.
- 41 Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. *Lancet* 2013; **381**: 133–41.
- 42 Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004; **328**: 1519.
- 43 Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013; **368**: 341–50.
- 44 Jung-Choi K-H, Khang Y-H, Cho H-J. Hidden female smokers in Asia: a comparison of self-reported with cotinine-verified smoking prevalence rates in representative national data from an Asian population. *Tob Control* 2012; **21**: 536–42.